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Abstract 
 
Eicosanoids play an essential role in platelet function as they can both stimulate and 
inhibit platelet reactivity. Current anti-thrombotic therapies include aspirin that 
inhibits the enzyme COX-1 and thereby the production of arachidonic acid (AA)-
derived, pro-aggregatory eicosanoids from platelets. Despite generally promising 
clinical outcomes, aspirin has limitations in efficacy and is associated with various 
side effects, highlighting the need for improved therapies. Eicosanoid synthesis can 
be altered by changes in substrate availability as well as by inhibition of pathway 
enzymes. For example, the omega-6 fatty acid dihomo-γ-linolenic acid (DGLA) can be 
utilized by platelets for the synthesis of anti-aggregatory eicosanoids, especially via 
pathways independent of COX-1, and can thus promote platelet inhibition.  
 
 The objectives of this thesis were therefore to investigate the effects of DGLA 
on platelet reactivity and further examine the DGLA effects together with aspirin.  
 
 In this study, I found that DGLA inhibits a variety of platelet functions, 
including platelet aggregation, adhesion, spreading and the surface expression of 
platelet activation markers. I further showed that DGLA inhibits α- and dense granule 
release and alters the platelet proteomic releasate profile, especially in the presence 
of aspirin. Pathway enrichment analysis predicted that addition of DGLA would 
further inhibit platelet-specific responses compared to aspirin alone, and might also 
influence inflammation and tissue repair, suggesting an exciting potential of DGLA to 
enhance therapeutic strategies for vascular diseases. Additionally, DGLA caused loss 
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in proteins linked to cytoskeletal rearrangement and initiated a unique physical 
phenotype in activated platelets similar to unstimulated platelets with curved 
elongations. Investigating the eicosanoid profile in response to DGLA, I found that 
DGLA did not alter the production of AA-derived eicosanoids, however, promoted 
the production of anti-aggregatory series-1 prostaglandins, 12-HETrE and the anti-
inflammatory 15-HETrE and 8-HETrE. While aspirin inhibited AA-derived prostanoid 
production, it only minimally reduced DGLA-derived prostaglandin production, 
suggesting the involvement of still uncharacterised production pathways.  
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1 CHAPTER – INTRODUCTION 
1.1 Platelets 
Blood platelets are small non-nucleated cells, that originate from megakaryocytes in 
the bone marrow and circulate in the blood stream of mammals. Platelets are 
essential for the process of haemostasis due to their ability to adhere to the damaged 
vascular surface, form platelet-platelet aggregates, activate and recruit leukocytes to 
the side of vascular injury and drive the accumulation of fibrin for clot stabilization 1. 
Separately to vascular injury by trauma, a variety of risk factors including obesity, 
smoking or diabetes can stimulate endothelial dysfunction and thereby the 
disturbance of the vessel wall 2. This dysfunction results in inappropriate activation 
of platelets in the vascular system which is fundamental to the development of 
atherothrombosis 3.  
1.1.1 Platelet structure 
Platelets are blood cells measuring between 2-5μm in length. In a resting state, they 
display a discoid shape which allows them to flow close to the vascular endothelium 
in the blood stream 4. Their plasma membrane consists of a phospholipid bilayer 
clustered with a variety of integral proteins and receptors. The membrane shows 
periodic protrusions into the internal cytoplasm, referred to as the open canalicular 
system (OCS). The OCS forms a complex network of membrane tubes that may play 
an important role in secretion and adhesion processes 5. Below the plasma 
membrane lays the cytoskeleton, composed of the actin filament system and an 
internal marginal microtubule coil consisting of tubulin heterodimers. Filaments of 
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actin build a network from the cytoplasmic core to the plasma membrane which 
allows them to regulate cell shape changes and motility and build a scaffold for 
receptors such as von Willebrand factor (vWF) and surface glycoproteins (GPs) that 
are essential to bind ligands such as collagen 6. Following platelet activation, 
reassembly of actin filaments stimulates a spherical platelet shape and the formation 
of filopodia. Binding of ligands such as fibrinogen or vWF to the platelet surface 
initiate aggregate formation that causes rapid cytoskeleton remodelling, formation 
of lamellipodia and stress ﬁbers 7. Next to changes in the actin cytoskeleton, the 
microtubule ring extends and coils together, which adds to the spherical shape of 
activated platelets 8, localizes internal organelles 9 and influences granule secretions 
10. Several proteins such as septins 11,12, talin 13 , heat shock proteins (HSPs) 14, the 
tyrosine kinase CSK 15  and tropomyosin16 are essential for correct cytoskeletal 
rearrangement that is tightly linked to secretion and formation of platelet-platelet 
aggregates. 
1.1.2 Platelet activation, adhesion and aggregation 
 The process from initial platelet activation to the production of aggregates is 
very complex and a variety of agonists have been identified that promote different 
signalling networks and enhance procoagulant properties and aggregation of 
platelets (figure 1.1). Two waves of aggregation have been recognised, the first wave 
of aggregation stimulated by initial agonist-mediated receptor activation and the 
second wave of aggregation that enhances activation and ensures aggregate stability 
by the release of bioactive mediators such as ADP and TXA2. 
 The main trigger for platelet activation following vascular tissue damage 
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involves the exposure of extracellular matrix components vWF and collagen under 
the endothelial layer 17. vWF binds to the GPIb subunit of the GPIb-IX-V complex 
while collagen binds to GPVI, essential for robust platelet activation, or GPIa/IIa 
(integrin α2β1) on the platelet surface, resulting in platelet adhesion and spreading 
on the vessel surface 18. Integrins are heterodimeric transmembrane receptors that 
show low affinity in the resting state and undergo conformational changes following 
platelet activation that exposes the external ligand binding side 19. In the high affinity 
state, integrins exert bidirectional signalling referred to as inside-out and outside-in 
signalling. While inside-out signalling activates the integrin function following 
platelet activation, outside-in signalling helps platelets to detect extracellular 
changes via alteration in ligand availability and alter responses such as cell spreading, 
migration and clot retraction 20. Several regulatory proteins for integrin-mediated 
signalling have been discovered including proteins linked to the actin cytoskeleton 
such as talin and its coactivator kindlin that play a role in both inside-out and outside-
in signalling 21. 
  Next to integrins, platelets express a large amount of G protein (guanine 
nucleotide-binding protein) coupled receptors (GPCRs). GPCRs are transmembrane 
receptors coupled to heterotrimeric G proteins with α and βγ subunits. Several G-
proteins occur in platelets such as Gq, Gs and Gi, that dissociate from their distinct 
receptors following platelet stimulation and activate specific subsets of downstream 
proteins, resulting in platelet activation or inhibition depending on the involved 
signalling cascade 22. Important GPCRs are the Gq-coupled protease-activated 
receptors (PAR), activated by thrombin, a serine protease produced during the 
coagulation cascade from pro-thrombin. Thrombin initiates conversion of soluble 
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fibrinogen to fibrin strands to stabilize the platelet clot and is a potent platelet 
agonist that triggers platelet activation by cleaving the tethered ligand of PAR 23. Low 
thrombin concentration activates platelets via the PAR1 receptor while PAR4 
requires higher concentration. Thrombin receptor activator peptide 6 (TRAP-6) is a 
synthetic agonist that is commonly used during experiments and activates PAR1 by 
mimicking the tethered ligand that is cleaved by thrombin. Following receptor 
stimulation, released Gq activates phospholipase C (PLC) that hydrolyses 
phosphatidylinositol 4,5- bisphosphate (PIP2) and mediates the production of the 
second messenger diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). While 
IP3 mobilizes internal calcium (Ca2+) stores from the endoplasmatic reticulum (ER), 
DAG activates the protein kinase C (PKC) that promotes activation of the GPIIb/IIIa 
receptor (integrin αIIbβ3) on the platelet surface via inside-out signalling. Integrin 
αIIbβ3 produces stable platelet aggregates through binding to fibrinogen 24 which 
activates outside-in signalling cascades that stimulate cytoskeletal rearrangement, 
platelet spreading and promotes thrombus stability 25. During this activation process, 
platelets change shape and release a variety of molecules from internal granules or 
from de novo synthesis that control cellular processes at the wound site, enhance 
platelet activation and stabilize newly formed aggregates. Membrane fusion of α-
granules, the most common granule subset in platelets, releases the content into the 
blood and translocates the adhesion molecule p-selectin to the platelet surface that 
stimulates platelet-leukocyte aggregates 3.  
 Secretion of dense granules releases adenosine diphosphate (ADP) that 
potentiates platelet responses by binding to the GPCRs P2Y12 and P2Y1 coupled to Gq 
and Gi, respectively, for both the platelet of origin and other platelets at the site of 
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vascular injury. P2Y1 mediates platelet activation via activation of PLC, subsequent 
rise in the cytosolic Ca2+ and platelet shape change, whereas P2Y12 activates the 
phosphoinositide 3-kinase (PI3K) and inhibits adenylate cyclase via Gi 26. While PI3K 
phosphorylates phosphoinositides that stimulate the activation of protein kinases 27, 
inhibition of adenylate cyclase prevents the production of anti-aggregatory, 
intracellular 3’,5’-adenosine monophosphate (cAMP) from ATP. Through all those 
pathways, the increase in the intracellular Ca2+ plays an essential role by mediating 
activation of several Ca2+-dependent enzymes including PKC, cytosolic phospholipase 
A2 (cPLA2) and the myosin light chain kinase (MLCK) for cytoskeletal rearrangement 
via phosphorylation of the myosin light chain (MLC). 
 cPLA2 is an enzyme that cleaves the sn-2 ester bond of cellular phospholipids 
in the platelet membrane, thereby causing the release of enzymatic substrates, 
particular arachidonic acid (AA, 20:4n-6) (figure 1.4 E), for the synthesis of signalling 
mediators such as thromboxane A2 (TXA2) that binds to surface receptors and further 
enhances platelet activation 28.  
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1.1.3 Platelet secretome 
When platelets are activated, they secrete a variety of active substances that are 
essential regulators of cells in the surrounding microenvironment and contribute to 
inflammatory processes and disease development. At the level of the platelet, these 
mediators are important to sustain correct function as some of them augment 
activation pathways and stabilize platelet aggregates. Important mediators include 
eicosanoids, oxidized fatty acids and potent signalling molecules, as well as a large 
variety of proteins released via granule and extra-cellular vesicle secretion. 
1.1.3.1 Platelet mediators 
1.1.3.1.1 Eicosanoids 
AA and other polyunsaturated fatty acids (PUFAs) play a significant role in platelet 
function as they are precursors for local signalling mediators, called eicosanoids. 
Eicosanoids are produced by a variety of different pathways involving constitutive or 
inducible enzymes but also via non-enzymatic pathways or transcellular mechanisms 
29. Production of eicosanoids is highly dynamic and both pro- and anti-aggregatory 
eicosanoids can be produced depending on substrate and enzyme availability and 
environmental cues 30,31. Following synthesis, they are rapidly released and trigger 
inter- and intracellular signalling cascades by binding to GPCRs or peroxisome 
proliferator-activated receptors (PPARs) 32,33.  
1.1.3.1.1.1 AA- derived eicosanoids 
Under physiological conditions, levels of free AA are kept low to prevent 
inappropriate platelet aggregation, however non-physiological conditions and 
platelet activation result in an increased availability of AA following release from the 
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phospholipid membrane. This AA is further converted into eicosanoids via enzymes 
including cyclooxygenases (COXs), lipoxygenases (LOXs) and cytochrome P450 
(CYP450) 28. Platelet COX-1 is the essential enzyme for TXA2 production and other 
platelet-derived prostanoids including prostaglandin (PG)E2, PGF2α 34,35 and PGD2 36 
(figure 1.2). For the formation of prostanoids in platelets, free AA is converted by 
COX-1 via two steps on two separate catalytic sites; firstly to PGG2 , the 
‘cyclooxygenase’ function that adds two oxygen molecules, and secondly to PGH2, a 
‘peroxidase’ function 34,37. PGG2 and PGH2 are known as endoperoxides and are very 
short lived. PGH2 is processed by specific downstream synthases into the biologically 
active eicosanoids that are rapidly released 35. 
 Depending on the released concentration, receptor selectivity and target cell, 
each prostanoid has distinct functionalities that can promote contrasting effects in 
the vasculature by binding to GPCRs. PGD2, that mainly binds to the platelet Gs-
coupled DP receptor inhibits platelet aggregation, while PGE2 acts on receptors EP1 
to EP4 and, dependent on concentration,  stimulates platelet activation or inhibition. 
PGF2α can bind to the EP3 receptor with low affinity and promote platelet activation 
31. From all AA-derived eicosanoids by platelets, TXA2 is the most important one as it 
strongly drives further platelet activation and aggregation by binding to the Gq-
coupled TP prostanoid receptor. The action of TXA2 is counter-balanced by the 
production of PGI2 (prostacyclin) from vascular cells which binds to the Gs-coupled IP 
receptor and acts to inhibit platelet activation via increase of cAMP 31. Next to the 
prostanoids, two other COX-1 products in platelets have recently been identified, 11-
hydroxyeicosatetraenoic acid (11-HETE) and 15-HETE, with 15-HETE displaying a 
potent effect on endothelial angiogenesis following release 38. Further research is 
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necessary to increase our knowledge regarding production and action of these lipid 
mediators.  
 Next to the well-known COX pathway, the enzyme 12-LOX plays a crucial role 
in the production of eicosanoids in platelets and has found to be essential for platelet 
activation 39. The main activity of 12-LOX consists of the oxidation of released AA to 
12-HpETE that is quickly reduced to 12-HETE 40. Despite the fact that 12-HETE is one 
of the mediators produced in the largest amounts by platelets, conflicting data, e.g. 
both pro- 41 and anti-aggregatory effects 42 have been reported, making it difficult to 
draw robust conclusions about its actual roles. A recent review by Porro et al. 
concluded that the function of 12-HETE varies depending on concentration, 
stereospecificity and incubation condition 43. Besides its reduction to 12-HETE, 12-
HpETE can take an alternative isomerization pathway that results in the formation of 
hepoxilins. It has been implied that oxidative stress such as induced during 
pathological shear stress 44 favours isomerization of 12-HpETE over reduction and 
therefore results in the production of hepoxilins 45. 
 AA can also be converted by CYP450 epoxygenases into the biologically active 
mediators epoxyeicosatrienoic acids (EETs). Several EET regioisomers have been 
identified including 5,6-, 11,12-, and 14,15-EET that are converted into their 
corresponding metabolites dihydroxyeicosatrienoic acids (DHETs) via hydrolysis of 
the epoxide group. EETs are generally more bioactive and have a variety of regulatory 
effects including influences on vasodilation, platelet aggregation and smooth muscle 
cell function 46. 
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Figure 1.2 Production of eicosanoids from AA in platelets 
AA: arachidonic acid, PG: prostaglandin, HETE: hydroxyeicosatetraenoic acid, HpETE: 
hydroperoxyeicosatetraenoic acid, TXA2: thromboxane A2, COX-1: cyclooxygenase 1, 12-LOX: 
12-lipoxygenase, EET: epoxyeicosatrienoic acids, DHET: dihydroxyeicosatrienoic acid, 
CYP450: cytochrome P450 
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1.1.3.1.2 Transcellular production  
 Next to intracellular production pathways, 12-LOX also plays a role in the 
transcellular synthesis of eicosanoids, such as during the production of lipoxins (LXs) 
between platelets and leukocytes (figure 1.3). In platelets, LXs are generated by cell 
to cell interaction, in which leucocytes produce the unstable tetraene intermediate 
leukotriene (LT) A4 via 5-LOX, that is then released and further metabolised by 
platelets via 12-LOX 47. 12-LOX catalyses the conversion of LTA4 to LXA4 or LXB4 via 
insertion of oxygen at the C14 or C6 position, respectively, thereby providing a dual 
enzymatical effect 48,49.  
Following release, LXA4 acts  on platelet formyl-peptide receptors (FPR) 50, 
with evidence suggesting that stimulation of FPR2/3 suppresses platelet adhesion, 
TXA2 formation, and platelet-neutrophil interaction 51,52. It has been shown that 
there is a comparable affinity of 12-LOX for AA and LTA4 leading to the production of 
12-HETE and LXB4, respectively. However, due to the rapid degradation rate of LTA4, 
AA might be favoured as a substrate due to its relatively higher availability 40. In 
addition to 12-LOX, it has been reported that platelets contain the enzyme LTC4 
synthase that in turn can convert LTA4 into 
LTC4 53. In contrast to the LTA4-derived 
product LXB4, LTC4 acts as a potent 
vasoconstrictor and has been linked to 
vascular disease development 54. The 
selectivity of leukocyte-derived LTA4 as a 
precursor for LXs or LTC4 production has 
been elucidated in a study from Romano & 
Figure 1.3 Production of eicosanoids from 
leukocyte-derived LTA4 in platelets 
LTA4, Leukotriene A4; 12-LOX, 12-
lipoxygenase; LX, lipoxin 
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Serhan 40, that showed that the interaction of platelets with leukocytes primarily 
occurs at a time point when platelets become permeable following aggregation and 
granule release. The authors showed that compared to intact platelets, 
permeabilized platelets produce increased amount of LXs relative to leukotrienes. 
The preference for LXs production might be explained by a sustained activation of 
12-LOX in permeabilized platelets. 
1.1.3.1.3 Proteins 
In addition to eicosanoids, activated platelets rapidly release a wide array of different 
peptides and proteins such as cytokines, chemokines and growth factors via 
secretion of granules and extracellular vesicles (EVs) 55,56. The platelet ‘secretome’ is 
easily accessible and alterations in protein levels following treatment or stimulation 
offer insights into changes in secretory mechanisms and potential effects on 
surrounding blood cells and vascular endothelial 56,57.  
1.1.3.2 Secretory Machinery 
The secretion of bioactive substances is one of the most important steps for 
controlled platelet function via para- and autocrine mechanisms and essential for 
inter-cellular communication to ensure successful haemostasis and vascular 
integrity. During releasate responses in platelets, proteins are secreted as cargo of 
internal granules or via formation of plasma membrane–derived EVs. Motor proteins 
are generally involved in cytoskeletal rearrangement and bidirectionally transport 
the cargo along the microtubule and actin filaments. Myosin works along the actin 
filaments, where as a dynein/dynactin complex together with kinesin motors act on 
the microtubules. It has been indicated that transport along actin is used for shorter 
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movements and cargo linkage to specific locations while microtubules are used for 
extended transport 58. Those processes are ATP dependent and crosstalk between all 
motor proteins is essential for correct secretion processes 59. It has been reported 
that release of platelet granules is mediated via an active process involving the 
Soluble NSF Attachment Protein Receptor (SNARE) complexes that regulate the 
fusion of granules with the platelet plasma membrane 60. 
1.1.3.2.1 Granules 
Platelets contain a variety of granule subsets, such as lysosomes, α-granules and 
dense granules, that are situated close to the OCS, fuse with the membrane following 
platelet activation and release their cargo into their immediate surrounding. The 
function of lysosomes is not well understood but might include the lysis of plasma 
proteins via release of degradative enzymes 61. α-Granules are the most abundant 
granules in platelets and contain a large array of proteins and cytokines that are 
classified by their distinct functions. These proteins include chemokines (e.g. CXCL4), 
angiogenic factors (e.g. endothelial growth factors), inflammatory mediators (e.g. 
complement factor C5) as well as proteins involved in adhesion processes (e.g. vWF, 
thrombospondin-1, fibrinogen). Additionally, granules contain proteins on their 
plasma membrane that are displayed on the platelet surface following granule 
fusion, these include integrins, p-selectin, immunoglobulins and leucine-rich repeat 
family receptors 62,63.  
 In contrast to α-granules, dense granules contain smaller molecules involved 
in cell signalling such as serotonin, Ca2+, ATP and ADP, that acts via positive feedback 
loops to potentiate platelet responses. It has been shown that platelets depend on 
the secreted ADP rather than plasma ADP for full aggregation as genetic-modified 
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mice lacking the process of dense granule secretion failed to aggregate and form 
thrombi 64.  
1.1.3.2.2 Extracellular vesicles 
As well as active granule release, platelets secrete EVs which play a key role in 
intercellular communication. EVs are small (100nm - 1μm) vesicles that ‘bleb’ from 
the phospholipid membrane and encapsulate internal organelles and mediators from 
the cytoplasm. This can occur spontaneously, under high shear conditions or 
following agonist-stimulated platelet activation. Several types of vesicles have been 
discovered and classified depending on size and generation processes. Platelet EVs 
account for over 90% of the plasma EVs in the blood stream and have often been 
considered as biomarkers for specific cardiovascular conditions as they display 
unique subsets of proteins derived from the parent cell. These include mediators 
derived internally but also surface proteins such as different GPs and p-selectin 65. 
1.1.3.3 Historic outlook on the measurement of platelet mediators via liquid 
chromatography – tandem mass spectrometry 
From their discovery in 1882 by G. Bizzozero until now, the roles of platelets in 
homeostasis and thrombosis have remained a strong research focus 66. The 1960’s 
were a time of great advances in platelet research with the group of Aaron Marcus 
conducting first experiments on platelet phospholipids in 1962 and just 5 years later, 
Warshaw and colleagues providing the first evidence that platelets contain proteins 
67,68. New research technologies that enabled sensitive detection of small molecules 
in biological systems were developed in the 1970’s and 80’s and inspired enhanced 
investigations into the synthesis of lipid mediators such as eicosanoids as well as 
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released proteins from platelets in response to different stimuli 69. This included 
intensive research into the effects of dietary supplementation on the lipid profile in 
platelets in cardiovascular diseases 66. 
 The so called ’‘Omics’’ era took place in the mid 2000’s when advances in 
mass spectrometry (MS) resulted in the development of an analytical technique that 
allowed liquid chromatography (LC) to separate and identify biological 
macromolecules in complex biological samples. These include carbohydrates, organic 
and inorganic compounds, proteins (‘’proteomics’’) and eicosanoids 
(‘’eicosanomics’’) 70. Through this combined approach, referred to as liquid 
chromatography – tandem mass spectrometry (LC-MS/MS), individual compounds 
are separated in a liquid mixture based on their polarity with the most polar 
molecules eluting first and the least polar ones last out of a non-polar column 71. 
Following separation, molecules are identified and classified depending on their 
mass-to-charge (m/z) ratio via a tandem approach (MS/MS) 57,72. Over recent years a 
variety of improvements in LC-MS/MS have allowed the development of high-
throughput analysis with high molecular specificity and detection sensitivity of both 
plasma and tissue samples. To date, several reviews including O’Donnell at al. 66 and 
Burkhart et al. 73 have summarized the historic perspective, achievements and future 
perspectives of lipidome and proteome analysis in platelets, respectively. 
 
1.2 Atherosclerosis and atherothrombosis 
 Atherosclerosis is a disease characterized by the development of plaques in 
the vascular system, depriving essential body parts of oxygen and nutrients by 
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inhibiting normal blood flow. Atherosclerosis already starts at an early age, emerging 
progressively via accumulation of cholesterol-rich lipids at the arterial intima and the 
subsequent development of a ‘’fatty streak’’. The accumulated lipids are oxidized and 
stimulate a chronic inflammatory response with the recruitment of monocytes and 
lymphocytes to the vessel wall. With increased lipid accumulation, the plaque 
matures into a lesion with a necrotic core and a fibrous cap that is susceptible to 
rupture 74. Plaque disruption can be stimulated by a variety of different factors 
including the local shear rate, hypercoagulation or injury of the vessel wall, based on 
the concept of the ‘‘Virchow’s triad’’ 75,76. Upon rupture, the necrotic core and 
underlying vascular components are exposed to the blood circulation causing 
activation and recruitment of platelets and other inflammatory cells to the side of 
vascular injury 77. Production of platelet aggregates, leukocyte activation and fibrin 
accumulation result into the production of a blood clot, also called thrombus. 
Depending on the location of thrombus formation, atherothrombosis can lead to leg 
ischemia, stroke or myocardial infarction, with the last two being the leading causes 
of mortality worldwide 78. Due to its unpredictable and life-threatening 
consequences, research regarding prevention and treatment of atherosclerosis and 
consequential thrombosis has been a priority for many clinical investigators.  
1.2.1 Anti-platelet therapies and their drawbacks 
 To date, patients with vascular diseases including coronary heart disease 
(CHD) and cerebrovascular disease are commonly treated with dual anti-platelet 
therapies consisting of aspirin, that irreversibly inhibits COX-1 and subsequent TXA2 
production, and P2Y12-receptor antagonists such as clopidogrel. Even though 
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efficacious to prevent further atherothrombotic complications in most patients, 
there is still a significant number of individuals that continue to experience recurrent 
ischemic events. Classified as low or-non-responders, those patients display failure 
to inhibit TXA2 production and incomplete inhibition of platelet reactivity despite 
standard aspirin treatment. Even though still inconclusive, this phenomenon has 
been linked to differences in genetic background causing changes in metabolic 
processes and platelet function such as increased platelet turnover resulting in faster 
platelet COX-1 recovery, or interactions with other drugs influencing 
pharmacokinetics 79,80. Simply increasing the doses of aspirin does not offer a solution 
as doses higher than 81 mg/day significantly potentiate the risk of developing side 
effects such as gastrointestinal bleeding 34,81. Similar findings have been documented 
when increasing the dose or treatment duration of P2Y12 inhibitors 82. Reoccurring 
thrombotic events have also been linked to the fact that aspirin is not platelet-
specific and can also suppress other COX isoforms expressed in the vascular system. 
It has been found that the dose required to block TXA2 production from platelets also 
supresses PGI2 synthesis from vascular cells and thereby could potentially increase 
the risk for cardiovascular events by preventing natural platelet inhibition 83.  
 A novel approach proposes the application of LOX inhibitors that reduce the 
production of HETE products from AA in platelets. A recent study has investigated 
the effect of ML355, a 12-LOX inhibitor, on platelet aggregation and thrombus 
formation and has found a significant reduction in experimental tests in vitro, ex vivo 
and in vivo 84. Further clinically relevant studies are necessary to increase insights 
into the possible side effects of a combination therapy as well as on the balance of 
eicosanoids produced by the COX/LOX systems. This is especially important as the 
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role of 12-HETE in platelet function is not completely understood (refer to chapter 
1.1.3 Platelet secretome) and could impact clinical effectiveness 31. To summarize, 
the clinical application and promising pre-clinical findings of anti-platelet therapies 
influencing the production of eicosanoids from platelets proves the importance of 
those mediators with regard to disease outcome and prevention. Further advances 
in technologies such as lipidomics continue to offer new insights into the complex 
network of eicosanoid synthesis and how changes in enzyme activity or substrate 
availability might influence eicosanoid production and subsequent platelet function. 
 
1.3 Dietary fatty acids 
Fatty acids play important roles in all parts of the body by supporting correct cell 
function and metabolism. They are a crucial energy source for metabolic processes, 
serve as gene regulators and are the main components of the cell membrane in the 
form of phospholipids. Fatty acids in the diet are commonly present in form of 
triglycerides 85. Triglycerides consist of two or more different fatty acids, esterified 
with glycerol. Most natural fats such as in plants and animals contain a mixture of 
triglycerides that consist of fatty acids with an even number of carbon atoms. Fatty 
acids are found as saturated (SAF; containing no double bonds between carbon 
atoms) or unsaturated fatty acids (containing a minimum of one double bond 
between carbon atoms). Stearic acid (SA, 18:0) is a non-essential SAF found in meat, 
fish, eggs and dairy products, but also in grains, fruits and vegetables 86 (figure 1.4 A). 
The average intake of SA ranges between 5-8 g/day, making SA the most common 
SAF next to palmitic acid 86,87. Fatty acids with more than one double bond are 
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referred to as PUFAs. Particular attention has been paid to omega-3 (ω-3) and 
omega-6 (ω-6) PUFAs, which have the first double bound between their third and 
fourth or sixth and seventh carbon atoms from the methyl group, respectively. 
 PUFAs are exclusively produced by plants and phytoplankton, however are 
essential to all mammals 88. As a result, humans are dependent on the intake of 
linoleic acid (LA, 18:2n-6) and alpha-linolenic acid (ALA, 18:3n-3), precursors of the 
ω-6 and ω-3 fatty acid chain, respectively (figure 1.4 B, C). Following intake, enzymes 
in animals and humans insert new double bonds and elongate the carbon chain to 
produce alternative fatty acids 89. Interconversion between ω-6 PUFAs and ω-3 
PUFAs is not possible, highlighting the importance of a balanced diet 90. Both LA and 
ALA are typically present in oils derived from plants including sunflower, canola and 
corn as well as in fish and red meat 91,92. An important product of LA is γ-linolenic-
acid (GLA, 18:3n-6) followed by the elongation product dihomo-γ-linolenic acid 
(DGLA, 20:3n-6), which will be discussed in more detail below (figure 1.4, D). DGLA 
can be further converted into AA (figure 1.4 E), that is an essential component of the 
phospholipid membrane and for eicosanoid production. Following intake, fatty acids 
can be stored in adipose tissue, used in muscle cells for energy production or further 
metabolised by several enzymes into bioactive signalling molecules that promote 
different effects depending on their precursor, which will be discussed in more detail 
in the following chapters.  
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1.3.1 The effect of fatty acid supplementation on cardiovascular diseases 
With increased research into the effects of dietary fatty acids on disease 
development, it has been found that SAFs can be associated with increased 
cardiovascular disease risk and are subsequently regarded as unfavourable for 
health. Based on the high intake of those fatty acids and the connection to rising 
cholesterol levels, several health and research associations have recommended a 
diet with an energy intake of SAFs just under 7% 93,94. To achieve maximal risk 
reduction, it has been implied that these fats should be substituted with PUFAs 95.  
 Previous research has shown that PUFAs are essential to maintain biological 
functions throughout all life stages as well as providing long-term health benefits 96,97 
Especially ω-3 PUFAs have been most rigorously studied and closely linked to the 
reduction of a significant variety of diseases such as cancer 98, arthritis 99, asthma 100 
Figure 1.4 Fatty acid 
structure 
Structure of stearic acid 
(A), linoleic acid (B), alpha-
linolenic acid (C), dihomo-
γ-linolenic acid (D) and 
arachidonic acid (E) 
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and cardiovascular diseases 101. On the other hand, ω-6 PUFAs have been associated 
with an increase in disease risk 102. However, studies investigating the effect of 
dietary ω-6 PUFAs on CHD risk and development have shown inconsistent clinical 
outcomes as summarized in a review article by Hooper and colleagues 103. Here, the 
authors studied the findings of 19 case-control trials with over 6000 participants and 
linked the contradictions and low-quality findings to variations in study designs (e.g. 
duration and dose of PUFA supplementation, type of disease) and limited knowledge 
about the impact of genetic diversity on the production of bioactive mediators. 
Nevertheless, a significant number of clinical trials linked LA and GLA to a reduction 
in cardiovascular disease risk and mortality, and those results were even more 
promising in in vitro and in vivo studies 104. Here, GLA supplementation provided an 
additional benefit over LA alone, as the enzyme Δ6-desaturase, responsible for the 
conversion of LA to GLA, is rate-limiting. As the elongation product from GLA and 
substrate for many bioactive mediators, DGLA offers an even more promising 
approach and has shown to successfully reduce atherosclerotic risk 105 and thrombus 
formation106 in mice and tumour growth in vitro 107. Even though those studies have 
indicated potential clinical benefits, no trials have investigated the effect of direct 
DGLA supplementation on cardiovascular disease outcome thus far.  
 However, a study following 417 acute cardiovascular disease patients has 
documented that decreased levels of circulating DGLA are predictive of an increased 
risk for long-term mortality 108 while a study run in 1977 showed a reduction in 
platelet aggregation after only 2 hours following oral supplementation with 1g DGLA 
in healthy volunteers, and that this effect was even more pronounced during 
sustained supplementation (five days to four weeks) 109. Both studies suggest that 
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DGLA has anti-thrombotic effects. Decreased platelet aggregation with DGLA 
treatment corresponded with increase in PGE1, a bioactive product of DGLA.  
 With advances in technologies to detect macromolecules in biological 
samples, many research teams have shifted their focus from dietary fatty acids to 
their metabolized products, i.e. eicosanoids, that can exert cardiovascular protective 
effects. This change started with the discovery of pro-resolving mediators (SPMs) 
produced from ω-3 PUFAs, by Serhan and colleagues in 2002, that stimulate 
resolution of inflammation and thereby offer a promising therapeutic approach in 
chronic inflammatory diseases 110,111. Those revolutionary findings inspired the 
development of new nutritional products containing concentrated SPMs instead of 
the traditional fatty acid supplements, and trials investigating their role in 
cardiovascular diseases are currently ongoing 112. Those promising outcomes 
propose an exciting potential of eicosanoids from fatty acids and research into the 
production and function of molecules derived from ω-6 PUFAs may increase our 
insights into disease development and lead to improved therapeutic strategies for 
the management of vascular disease. 
1.3.2 Fatty acids in the system - lipid digestion, absorption and transport 
Understanding the effects of dietary fats in the vascular system requires knowledge 
of digestion, absorption, transfer in the blood and release from tissue, as all those 
factors influence the bioavailability of fatty acids to target cells. The intestinal 
absorption as well as metabolism and storage in tissue of triglycerides highly depends 
on the type of fatty acid, specifically their saturation status and carbon chain length. 
Following ingestion, triglycerides are broken down into free fatty acids and glycerol 
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by pancreatic lipase and bile salts in the intestinal lumen 113 (figure 1.5). Short-chain 
fatty acids can be directly absorbed into the blood via the capillaries of the intestine, 
however long-chain fatty acids, including PUFAs, show a very low solubility in water-
based solutions such as blood plasma. To allow the transfer through the blood 
capillaries, fatty acids are re-esterified into triglycerides, coupled together with 
cholesterol esters and packed into a non-polar lipid core that is surrounded by 
phospholipids and proteins 114. Also called chylomicrons, those lipoprotein particles 
are secreted from the enterocyte cell lining of the intestines into the lymph system 
and from there transported into the bloodstream. This process is also referred to as 
the exogenous pathway. In the blood, chylomicrons mature and allow the 
hydrolyzation of triglycerides into free fatty acids by lipoprotein lipases (LPL) present 
on vascular endothelial cells. Subsequent uptake of fatty acids into adipocytes or 
skeletal muscle cells for storage or as an energy source, respectively, is a highly 
regulated process that is influenced by hormonal and metabolic factors 115. After 
release of the fatty acids, remnant chylomicrons high in cholesterol are cleared by 
the liver from the circulation 116. Next to storage of cholesterol, the liver is also 
involved in the uptake of excessive circulating free fatty acids and formation of 
triglycerides.  
 Alternatively, cholesterol and fatty acids reincorporated into triglycerides are 
transported into the blood from the liver in the core of very low-density lipoproteins 
(VLDL) via the endogenous pathway. Similar to chylomicrons, VLDL particles interact 
with LPL and release fatty acids for uptake into the tissue. The depleted VLDL 
particles return to the circulation and are referred to as intermediate density 
lipoprotein (IDL), which are rich in cholesterol but have lost most of their 
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triglycerides. The IDL are either rapidly removed from the plasma into the liver or 
remain in the blood circulation where they are further degraded to low density 
lipoproteins (LDL). LDL particles are the main supplier of cholesterol via receptor-
mediated uptake to cells in the periphery such as to the kidney or adrenal glands 
which is essential for correct cell function and the production of hormones 117.  
 High density lipoproteins (HDL) particles are formed following uptake of 
cholesterol and phospholipid that are secreted from peripheral tissue, also referred 
to as reverse cholesterol transport. HDLs transfer cholesterol either directly to the 
liver or stimulate the uptake to VLDL or LDL. While remnant chylomicrons, VLDLs, 
IDLs and LDLs are considered pro-atherogenic, HDLs are considered anti-atherogenic 
and anti-inflammatory 118. In addition to lipoproteins, a small amount of fatty acids 
are bound by blood albumin to facilitate the transport to tissues during times of 
energy need 114.  During energy expenditure such as during fasting or exercise, stored 
fat in adipose tissue is released as free fatty acids via lipolysis into the blood stream. 
High levels of circulating free fatty acids as observed in obesity has been linked to 
endothelial dysfunction, chronic leukocyte activation and insulin resistance 119. 
 While supplementation with GLA has shown to increase DGLA plasma 
concentration, fatty acid compensation is generally displayed in percentage of total 
serum phospholipid content, making it difficult to relate dose of intake to final 
plasma concentration following digestion 120–122. 
.  
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1.4 Effects of fatty acids on platelet function 
Over decades it has been known that fatty acids play a pivotal role in the modulation 
of membrane structures and are essential for a variety of cell functions. However, 
research in platelets remains limited and studies investigating the effects of fatty 
acids were mainly conducted in the 1960’s and 1970’s and have not been replicated 
since. What has been discovered so far is that fatty acids influence intracellular 
signalling pathways in platelets by binding to surface receptors, being incorporated 
into the plasma membrane as well as being directly utilized for energy production via 
mitochondrial oxidation or utilized for eicosanoid synthesis. 
1.4.1 Uptake by platelets 
Following lipolysis of triglycerides in tissue stores, free fatty acids appear in the 
circulation in non-esterified form. These fatty acids quickly bind to plasma albumin, 
the most abundant protein in the blood (40mg/ml plasma) 123. Albumin contains 
several binding sites and its affinity to specific fatty acids increases with their carbon 
chain length 124. Interestingly, there seems to be an active exchange between fatty 
acids in the blood plasma and circulating cells as the dietary fatty acid composition is 
directly reflected in plasma, platelet and erythrocyte lipid profiles. Even though 
platelets only have a short-half life, accumulation of platelet lipids can be used as 
biomarker for short-term changes in fat intake 125.  The process of binding and 
uptake of fatty acids by platelet has barely been investigated. Early studies found that 
platelets remove fatty acids from the primary binding side of albumin via an active 
mechanism 126,127, potentially by binding to albumin via a specific receptor 128, as 
albumin has a higher affinity to fatty acids than platelets. Additionally, a high fatty 
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acid/albumin ratio with excessive levels of free fatty acids in the surrounding medium 
allows an enhanced uptake by platelets 129. To overcome the cellular lipid bilayer, 
different mechanisms of fatty transfer have been investigated and it appears these 
are limited to direct diffusion or active transportation catalyzed by specific protein 
receptors or transporters. During free diffusion, fatty acids move through the lipid 
membrane in their un-ionized form via the flip-flop mechanism 130. Diffusion occurs 
readily in experimental situations where cells are suddenly exposed to large amounts 
of unbound fatty acids 131. The rate of permeability via flip-flop is not influenced by 
carbon chain length, allowing a fast translocation of numerous fatty acid species 132, 
however it is directly proportional to the extracellular fatty acid concentrations. That 
direct absorption is the preferred way for fatty acid uptake in platelets was first 
demonstrated by Spector and colleagues who showed that transfusion of fatty acids 
through the platelet lipid membrane occurs rapidly and independent of temperature, 
suggesting an energy-independent mechanism 127.  
 On the other hand, a variety of membrane proteins that bind fatty acids and 
catalyze their transport through the cell membrane have been discovered. Again, 
research in platelets is limited, although one study showed that CD36, a lipoprotein 
receptor, is involved in fatty acid uptake 133. However, recent studies have shifted the 
focus to the role of CD36 in platelet adhesion and intracellular signaling 134–136. In 
platelets, Cohen and colleagues labelled fatty acids with the radioactive isotope 14C 
and found that platelets facilitate a stronger uptake of SAFs, including SA, than of 
PUFAs, such as LA, which has also been confirmed by Spector’s group 127,129. This 
implies that platelets display different affinities to fatty acids depending on their 
saturation status, however the specific mechanisms of uptake remain unclear. 
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1.4.2 Internal utilization 
Following their uptake into cells, fatty acids undergo a constant transfer between 
different compartments and are converted into metabolites depending on the 
requirements. It has been proposed that different pools of fatty acids present in 
platelets are located close to the plasma membrane allowing a fast transport 
between the lipid membrane, the internal locations and the surrounding medium 127. 
Spector’s group found that at the beginning of incubation (2-5 minutes (min)), fatty 
acids are mainly present as free fatty acids (85%) in platelets whereas with increased 
incubation time (up to 60min) and continuing uptake, fatty acids are rapidly 
incorporated into phospholipids via esterification (36%) or oxidized to CO2 (35%) and 
only a small amount remains present as free fatty acids (25%). Increase of the fatty 
acid/albumin ratio in the solution lead to a higher percentage increase of free fatty 
acids compared to their metabolites and more SAFs than unsaturated fatty acids 
remained as free fatty acids 127. Even though this study provides us with promising 
findings of fatty acid utilization in platelets, it was conducted nearly 50 years ago and 
lacks the application of modern sensitive techniques and offers no insights into 
eicosanoid production. 
1.4.2.1 Phospholipids 
In all cells of the human body, including platelets, fatty acids are the main 
components of the plasma membrane in form of phospholipids. Phospholipids 
consist of two hydrophobic fatty acid tail chains as well as a hydrophilic head group 
that allows the formation of a bilayer in an aqueous medium 137. Depending on the 
head group, a phospholipid can be classified as phosphatidylcholine, 
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phosphatidylserine (PS), sphingomyelin and many more. In those arrangements, 
fatty acids provide structural stability and a foundation for numerous 
transmembrane signalling molecules including receptors and surface lipoproteins. 
The most common phospholipid in platelets is phosphatidylcholine which can 
contain a variety of fatty acids. AA (13.5%) is the most common fatty acid 
incorporated in phosphatidylcholine followed by LA (7.9%) and DGLA (2.1%). To 
lesser extent, also omega-3 fatty acids can be found such as docosahexaenoic acid 
(DHA; 0.6%), eicosapentaenoic acid (EPA; 0.2%) and ALA (0.1%) 138. 
 During integration of fatty acids into phospholipids, long chain acyl-coenzyme 
A (CoA) synthetase forms an acyl-CoA ester that traps the fatty acids inside the cell 
and stimulates rapid esterification into cellular lipids 130. This reaction is catalysed by 
acyl-CoA synthetases specific for individual fatty acids, including a highly sensitive 
and efficient synthetase for selective AA incorporation and a synthetase with lower 
activity and specificity for the incorporation of a broader range of fatty acids. Thus, 
exogenous AA is quickly converted into platelet phospholipids following uptake, 
whereas other fatty acids including SA and LA accumulate in the internal FA pool 
130,139.  Nevertheless, several studies have shown that dietary supplementation with 
fatty acids other than AA leads to a competition for space in the membrane, causing 
a change in the lipid ratio. Especially SAFs seem to be more rapidly incorporated at a 
given extracellular concentration compared to PUFAs 127 and show distinct pattern 
of incorporation into specific classes of phospholipids 129. Alteration in the lipid 
profile of the membrane has been directly linked to changes in plasma protein 
expression and activity, subsequent intracellular signaling and production of 
eicosanoids following platelet activation 140.  
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1.4.2.1.1 Lipid rafts 
During activation, platelets undergo a drastic shape change via development of 
filopodia that allow the attachment to the endothelium and other platelets for 
aggregation. This process is regulated by the cytoskeleton that interacts with 
transmembrane proteins accumulated in specific lipid domains in the plasma 
membrane (refer to chapter 1.1.1 Platelet structure). Those areas, known as lipid 
rafts, are commonly enriched in cholesterol and sphingomyelin 141. Interestingly, 
those esters are mainly formed from SAFs and only minimal concentrations of PUFAs 
are found 142. This is most likely due to the fact that each double bond in the fatty 
acid chain increases the fluidity and decreases the thickness of the membrane, 
making it difficult to stabilize plasma proteins 137. Specifically, it has been 
demonstrated that supplementation with ω-6 PUFAs decreases the amount of 
cholesterol in lipid rafts which is a critical component to promote the formation of 
multiprotein complexes. On the other hand, increased ω-3 PUFA ratio stimulates 
clustering of lipid rafts and delocalization of signalling molecules 143. Together, 
changes in the fatty acid ratio of the lipid membrane alters the lateral diffusion of 
proteins and anchored receptors, such as GPVI and GPRCs for thrombin, TXA2 or ADP, 
and influences numerous signal transduction mechanisms involved in platelet 
activation or cell mobility 142. Additionally, changes in the membrane composition 
results in an altered profile of released fatty acids following platelet activation and 
modifies mediator metabolism and platelet functionality (refer to chapter 1.1.3 
Platelet secretome and 1.4 Effects of fatty acids on platelet function)  144. 
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1.4.2.2 Eicosanoids derived from ω-6 PUFAs 
The production of eicosanoids plays an essential role in platelet function due to their 
potent abilities to influence platelet activation and aggregation. Under normal 
conditions, AA is released from the phospholipid membrane and metabolized into a 
variety of bioactive mediators such as TXA2 that stimulate platelet aggregation. 
Experiments causing changes in dietary fatty acid intake have shown that eicosanoid 
synthesis highly depends on the size and availability of the precursor pool and that 
both ω-3 and ω-6 PUFAs (figure 1.4) can replace AA as a substrate for eicosanoid 
production 145–147.  
 As previously discussed, platelets incorporate diet-derived fatty acids into 
their membranes resulting in an altered phospholipid profile (refer to chapter 1.4.2.1 
Phospholipids). Platelets can only utilize free fatty acids for eicosanoid production, 
so, like AA, those fatty acids are liberated via cPLA2 cleavage following platelet 
activation and are further oxidised by the three major oxygenases COX, LOX and 
CYP450. Therefore, supplementation with specific dietary fats offers another 
strategy to decrease pro-inflammatory and pro-aggregatory eicosanoids, in addition 
to treatment with COX-1 or 12-LOX inhibitors, as some alternative lipid mediators 
can promote anti-aggregatory effects on platelets 144. The most well-known 
metabolite of LA is AA; however, LA is first metabolized to DGLA. DGLA has recently 
been shown to inhibit platelet aggregation both directly 148 and when supplied as 
dietary supplement 109 most likely via the production of eicosanoids independent of 
the AA-pathway 39,107.  
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1.4.2.2.1 LA-derived eicosanoids 
Following intake and absorption in target cells, PUFAs can be converted by 
desaturase and elongase enzymes that add a double bond or carbon atom to  the 
carbon chain, respectively 149,150.  LA undergoes a variety of conversion steps first to 
GLA via the action of Δ6-desaturase, that inserts an additional double bond, followed 
by elongation of the carbon chain to DGLA. DGLA is then further metabolized to AA 
by Δ5-desaturase (figure 1.6). Therefore, it has been suggested that enhanced LA 
intake could lead to increase of AA and subsequent production of pro-inflammatory 
and thrombotic eicosanoids such as TXA2. However, several studies have found that 
dietary supplementation with LA replaces AA in the phospholipid membrane, is 
released alternatively upon platelet activation and decreases synthesis of TXA2 151. In 
this context, it has been proposed that LA possibly inhibits COX-1 152, however no 
further evidence could be found to verify this hypothesis.  
 With additional research into the metabolism of LA it has been found that 
both Δ6 and Δ5-desaturase are rate-limiting and only convert a limited amount of 
the fatty acids to AA and the subsequent downstream products 92,150. Alternatively, 
LA can serve as a substrate for COX-1 and other enzymes and can be directly 
converted into eicosanoids, which together explains the decrease of TXA2. An 
important enzyme is CYP450, that converts LA into epoxyoctadacamonoenoic acids 
(EpOMEs). Similar to the EET metabolism from AA, EpOMEs are quickly converted 
into a stable product dihydroxyoctadecenoic acids (DiHOMEs) by soluble epoxide 
hydrolases (sEH). Two important EpOMEs, 9,10 – and 12,13 – EpOME, referred to as 
leukotoxins, are released in large amounts by activated leukocytes and are commonly 
considered to be pro-inflammatory 46,153. Their metabolites DiHOMEs are considered 
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to exert cytotoxic effects and have been linked to organ failure 154. Besides 
leukocytes, platelets also express CYP450 so it can be suggested that they also 
produce those mediators. However, stimulation of whole blood with a variety of 
platelet agonists such as collagen and TRAP-6 did not alter the production of 9,10- 
and 12, 13-EpOME 38. More research is necessary to further elucidate the production 
and function of those LA-derived epoxygenase products in platelets.  
 Other products derived from LA are hydroxyoctadecadienoic acids (HODEs), 
including 9- and 13-HODE. The biosynthesis of these mediators can be mediated by 
several pathways including COX, LOX, CYP450 and via autooxidation in both platelets 
and endothelial cells 155,156. 
1.4.2.2.2 DGLA-derived eicosanoids 
DGLA is the direct elongation product from GLA and is not only the precursor for AA, 
catalysed by Δ5-desaturase, but also for the potent platelet-inhibitory metabolites, 
PGE1 via COX-1 catalysis 157, and 12(S)-hydroxyeicosatetrienoic acid (12-HETrE), via 
12-LOX 138 (figure 1.6). Both PGE1 and 12-HETrE, that is produced in higher levels, 
exert their functions by binding to the Gs-coupled GPCRs prostacyclin (IP) platelet 
receptor 138,158,159. Limited evidence also suggests binding affinity to EP2 and EP4 
receptors 32. While COX-1 prefers AA over DGLA as a substrate 160, 12-LOX catalyses 
DGLA preferably and with faster turnover 39. It has been indicated that increase in 
DGLA results in the reduction of AA-derived products and an increase in mediators 
derived from DGLA, most likely because of the rate-limiting activity of Δ5-desaturase 
that is responsible for the conversion of DGLA to AA 107. Additionally, Δ6-desaturase, 
responsible for the conversion of LA to DGLA, shows limited activity and has been 
linked to a variety of disease pathologies such as diabetes, arthritis and 
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cardiovascular disease. Thus, direct DGLA supplementation offers the possibility to 
bypass this metabolic step and cause rapid production of PGE1 and 12-HETrE, which 
have shown promising influences upon pathologies such as cardiovascular disease 
and cancer 161.  
 A recent paper from 2016 provided insights into the beneficial effects of DGLA 
on platelet function. Here, platelets from wildtype mice were stimulated with 
collagen in the presence of several fatty acids. It was found that DGLA significantly 
decreased platelet aggregation over a time course of 5min. Additionally, the authors 
found that 12-LOX, and conclusively 12-HETrE, is required for the inhibitory effect of 
DGLA. This benefit could also be observed in vivo, as treatment with 12-HETrE 
decreased platelet aggregation and thrombus formation 159. Taken together, these 
findings support a potential role for DGLA and LA in mediating anti-platelet and anti-
thrombotic effects via changes in the balance of eicosanoid production. To date, only 
PGE1 has been investigated as an anti-thrombotic agent in humans. The fast 
metabolization of PGE1 prevents dietary supplementation approaches 109, however 
promising results have been indicated using a high-dose PGE1 drip infusion in 
addition to stent placement for arteriosclerotic occlusive lesion treatment. In these 
studies, PGE1 has been found to significantly improve the clinical outcome by 
decreasing platelet deposition and the production of microthrombi in cardiovascular 
disease patients 162. 
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Figure 1.6 Production of eicosanoids from LA and DGLA in platelets 
LA: linoleic acid , DGLA: dihomo-γ-linolenic acid, EpOMEs: epoxyoctadacamonoenoic acids, 
DiHOMEs: dihydroxyoctadecenoic acids, HODE: hydroxyoctadecadienoic acids, GLA: 
Gamma-linoleic acid, PGE1: prostaglandin E1, 12-HETrE: 12(S)-hydroxyeicosatetrienoic acid, 
COX-1: cyclooxygenase 1, 12-LOX: 12-lipoxygenase, CYP450: cytochrome P450 
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1.5 Summary 
Platelets play a key role in haemostasis. However, inappropriate platelet activation 
can lead to the development of thrombosis, the underlying process for 
cardiovascular pathologies such as myocardial infarction and stroke. During 
activation, platelets undergo a variety of functional and mechanistic changes 
including alteration of the cytoskeleton, secretion of proteins via EVs and granule 
release and the exposure of receptors on the platelet surface that initiate adhesion 
together with platelet-platelet and platelet-leukocyte aggregates.  
 Production of platelet-derived eicosanoids, metabolized from the ω-6 PUFA 
AA, plays an important part in governing platelet reactivity. It has been found that 
targeting eicosanoid production by influencing signalling pathways or substrate 
availability can lead to altered platelet reactivity. In particular, current anti-
thrombotic therapies include aspirin that blocks the enzyme COX-1 and thus 
preventing the production of pro-aggregatory eicosanoids from platelets and 
subsequent platelet activation. Even though aspirin has beneficial effects in most 
patients, there are still some individuals who have recurrent cardiovascular events 
while receiving aspirin treatment and increasing doses can increase the risks of 
gastrointestinal bleeding. Current advances in therapies, such as the addition of 
P2Y12-receptor antagonists, produce further reductions in thrombotic complications, 
however there are still significant limitations that need to be overcome.  
 Several studies have shown the beneficial effects of PUFAs in cardiovascular 
disease and one important mechanism involves the alteration of the substrate pool 
for eicosanoid biosynthesis. For example, the ω-6 PUFAs LA and DGLA can be 
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converted into eicosanoids that reduce platelet reactivity, independent of COX-1. 
Further investigating the effects of combined therapies of aspirin together with ω-6 
PUFAs such as DGLA, targeted to better balance eicosanoid production can help to 
shed light on the complex mechanisms involved in platelet function and on the 
potential for improved strategies to protect against pathological events associated 
with platelet activation. 
 
 
1.6 Hypothesis and aims 
This thesis will investigate the hypothesis that DGLA can inhibit platelet reactivity by 
altering essential platelet mechanisms and potentiate the inhibitory effects of aspirin 
by further altering eicosanoid production.  
To that end, the particular experimental aims are: 
 
1. To establish the effect of DGLA on important platelet functions, including 
aggregation, adhesion and secretion 
 
2. To investigate the response of platelets to a dual treatment approach of DGLA 
together with aspirin 
 
3. To shed light on the mechanistic changes leading to reduced platelet 
reactivity with DGLA 
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2 CHAPTER – MATERIALS 
 
Acetonitrile Sigma-Aldrich, UK 
Acetylsalicylic acid (aspirin) Sigma-Aldrich, UK 
Adenosine diphosphate (ADP)  Labmedics, UK 
Alexa-488 anti-mouse Fisher Scientific, UK 
Alexa-488 phalloidin Thermofisher Scientific, UK 
Alexa-647 Phalloidin Thermofisher Scientific, UK 
Ammonium Bicarbonate Sigma-Aldrich, UK 
Annexin V binding buffer Biolegend, UK 
APC Annexin V antibody Biolegend, UK 
APC anti-human CD36 antibody Biolegend, UK 
APC anti-human CD61 antibody Thermofisher Scientific, UK 
APC anti-human CD62P (P-Selectin) antibody Biolegend, UK 
APC anti-human CD63 antibody Biolegend, UK 
Arachidonic acid (AA) Sigma-Aldrich, UK 
AR-C 66096 tetrasodium salt Tocris Biotechne, UK 
BD LSRII Flow Cytometer BD Bioscience, UK 
Bioshake plate IQ shaker Quantifoil, Germany 
Bovine serum albumin Sigma-Aldrich, UK 
Brilliant Violet 42 anti-human CD42b antibody Biolegend, UK 
Calciumchloride (CaCl) Sigma-Aldrich, UK 
Collagen-related peptide (CRP) University of Cambridge, UK 
COmplete Tablets EASYpack - Protease inhibitor 
cocktail tablets 
Roche, Switzerland 
D-(+)-GLUCOSE Sigma-Aldrich, UK 
Diclofenac Barts Hospital Pharmacy, UK 
Di-homo-gamma linolenic acid (DGLA) Enzo Life Sciences, UK 
Disodium phosphate (Na2HPO4) (anydrous) Fisher Scientific, UK 
Donkey serum  Sigma-Aldrich, UK 
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Eptifibatide acetate Sigma-Aldrich, UK 
Ethanol vWR, UK 
Fibrinogen  Sigma-Aldrich, UK 
FITC anti-human PAC-1 antibody BD Bioscience, UK 
Formic acid (98%) Fisher Scientific, UK 
Graphpad Prism version 8 software Graphpad Inc, USA 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)  
Sigma-Aldrich, UK 
Image-iT TMRM Reagent Thermofisher Scientific, UK 
ImageJ software NIH, USA 
IN Cell Analyzer 6000 GE Healthcare Bio-Sciences, 
USA 
IN Cell Developer software (Version 1.9.1)  GE Healthcare Bio-Sciences, 
USA 
Ingenuity Pathway Analysis software Qiagen, Germany 
Iodoacetamide Sigma-Aldrich, UK 
Lablyo Mini freeze dryer Frozen in time Ltd, UK 
Linoleic acid (LA) Cayman Chemical, USA 
LSM 710 confocal microscope Zeiss, Germany 
Magnesium chloride (MgCl2) Sigma-Aldrich, UK 
MaxQuant Max Planck Institute, 
Germany 
Millipore C18 ZipTip (96) Sigma-Aldrich, UK 
Monoclonal α-Tubulin antibody (mouse) Sigma-Aldrich, UK 
Nanosight NS300 Malvern, UK 
NovoCyte Flow Cytometer ACEA Biosciences USA 
NTA2.1 software Nanosight, Malvern, UK 
PAP8 Aggregometer Bio Data Corporation, USA 
Paraformaldehyde vWR, UK 
Partek Flow Thermofisher scientific 
Partek Genomics Suite Software Thermofisher scientific 
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Perseus software Max Planck Institute, 
Germany 
Phosphate buffered saline (PBS) Sigma-Aldrich, UK 
PhosSTOP Phosphatase Inhibitor Cocktail Tablets Sigma-Aldrich, UK 
Poly-l-lysine coverslips Fisher Scientific, UK 
Potassium chloride (KCl) Sigma-Aldrich, UK 
Prolong Diamond Mount  Thermofisher Scientific, UK 
Prostaglandin E1 Sigma-Aldrich, UK 
Q Exactive UHMR Hybrid Quadrupole-Orbitrap 
Mass Spectrometer 
Thermofisher Scientific, UK 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, UK 
Sodium Chloride (NaCl) Sigma-Aldrich, UK 
Sodium hydroxide (NaOH) Fisher Scientific, UK 
Stearic acid (SA)  Cayman Chemical, USA 
Stir bar, magnetic teflon coated for P/N 312 
cuvettes 
Labmedics, UK 
Test Tubes for PAP8 Aggregometer Brennans, UK 
Thrombin Sigma-Aldrich, UK 
Thrombin receptor-activating peptide 6 (TRAP-6) Bachem, UK 
Trichloroacetic acid Sigma-Aldrich, UK 
Trifluoroacetic acid Sigma-Aldrich, UK 
Trisodium citrate Sigma-Aldrich, UK 
Triton Sigma-Aldrich, UK 
Trypsin Promega, USA 
Urea Sigma-Aldrich, UK 
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3 CHAPTER - MAIN METHODOLOGY 
3.1 Blood collection and platelet isolation 
NHS St. Thomas’s Hospital Research Ethics Committee approved all experiments 
using human blood (REC reference 07/Q0702/24). Blood from healthy volunteers 
was obtained via venous puncture into tri-sodium citrate (3,2%) after obtaining a 
written consent and a medical screening including heart rate, temperature and blood 
pressure in addition with a medical history questionnaire. Donors were required to 
abstain from any pharmacological agents known to alter platelet function, to be non-
smokers and under the age of 40. The citrated blood was centrifuged (175 x g, 15min) 
and the platelet-rich plasma (PRP) supernatant was removed and incubated in a 
water bath at 37°C until required. PRP extracted from blood is commonly used in 
platelet research as it is easy to obtain and offers a relatively pure and homogeneous 
platelet population. Platelet-poor plasma (PPP) as a positive control for 100% 
aggregation was obtained by centrifugation of the interphase at 12000 x g for 2min. 
3.2 Measurement of platelet aggregation 
To measure platelet aggregation, I utilized the Optimul platelet aggregometry assay 
and LTA (figure 3.1). LTA was developed in the 1960’s and is still considered the gold 
standard for testing platelet responsiveness 163. In contrast to Optimul that measures 
final platelet aggregation 164, LTA allows dynamic measurements under stirring 
conditions and the observation of time-dependent processes such as disaggregation. 
In both cases, platelets are incubated with physiological agonists, such as ADP or 
TRAP-6 to stimulate different activation pathways. Experimental setup and 
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concentrations used are indicated in each individual chapter. Platelet aggregation is 
evaluated by measuring the optical density of PRP, which decreases with the 
formation of aggregates that follow from the addition of exogenous platelet agonists. 
The outcome is normalized to measures for untreated PRP and PPP as standards for 
0% and 100% aggregation, respectively. To test responses to aspirin, PRP was 
incubated with aspirin (30μM) or vehicle (0.05% ethanol/PBS) for 30min in a water 
bath. To prevent autoxidation and ensure stability of the ω-6 PUFAs, AA, LA, SA and 
DGLA were stored in ethanol under inert gaseous nitrogen at -80°C and diluted in PBS 
to the required concentration immediately before the experiment. 
Figure 3.1 Assays to measure platelet aggregation 
Optical multichannel (Optimul) platelet aggregometry (A), light transmission aggregometry 
(B) 
62 
 
3.3 Statistical analysis 
Graphs and statistical analysis were generated using GraphPad Prism 8 (GraphPad 
Software Inc. USA) and described in each results section. 
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4 CHAPTER - INVESTIGATING THE EFFECT OF Ω-6 PUFAS ON 
PLATELET REACTIVITY  
4.1 Introduction 
Platelets are essential for haemostasis and play a key role in thrombosis which is the 
leading cause of death in the world. The production and release of eicosanoids plays 
an important role in promoting platelet activation and stabilizing the platelet 
aggregate. As a result, molecules targeting eicosanoid production such as aspirin, 
which inhibits the enzyme COX-1, subsequent TXA2 production and platelet 
aggregation, are commonly used as treatment for pathological events associated 
with platelet activation. Eicosanoid formation can also be influenced by alterations 
of fatty acids in the diet 145–147. For example, the ω-6 PUFA, DGLA, can be oxidised via 
COX-1 to PGE1 and via 12-LOX to 12-HETrE and inhibits platelet aggregation both ex 
vivo and in vivo 159.  As well as single therapy with aspirin, platelet inhibitory 
treatments in the clinic include dual treatment of aspirin in combination with P2Y12 
inhibitors such as clopidogrel. These inhibitors prevent activation of ADP-P2Y12-
dependent pathways through inhibition of Gi signalling, subsequent inhibition of PI3K  
and increase in adenylyl cyclase activity that stimulates cAMP-dependent protein 
kinase A (PKA)-catalysed phosphorylation of target proteins 165. Despite high 
efficiency to prevent further thrombotic events in most patients, around 48% of 
individuals show low responsiveness to one or both anti-platelet therapies, which 
significantly increases the risk for developing side effects such as stent thrombosis 
166,167.  Interestingly, there have been indications that both PGE1 and 12-HETrE 
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stimulate cAMP/PKA pathways by binding to the Gs -coupled IP receptor 106,107.  
 For this thesis investigation, I hypothesised that DGLA might reduce platelet 
reactivity and enhance aspirin-mediated inhibition of those responses, as both 
aspirin and DGLA influence eicosanoid production in platelets. Additionally, I was 
interested in the responses to the DGLA precursor LA and SA, a saturated fatty acid, 
which is one of the most common long-chain fatty acids in animal fats 168.  
 For first insights into effects of PUFAs on platelet function, I utilized a variety 
of aggregation assays which are established key methodologies to determine platelet 
reactivity in vitro. In these assays, platelets are incubated with increasing 
concentrations of physiological agonists, such as ADP, that bind to the P2Y1 and P2Y12 
receptors, or synthetic agonists such as TRAP-6, that acts as a PAR1 agonist, to 
stimulate different activation pathways. The formation of platelet aggregates is then 
commonly identified via LTA or related approaches, such as Optimul, which measure 
changes of optical density in the sample. Here, I studied the effect of aspirin in 
combination with different PUFAs and I also conducted initial experiments to shed 
light on the effect of DGLA on platelet aggregation following treatment with aspirin 
in combination with a P2Y12 inhibitor. 
 In addition to following aggregatory responses, I investigated the effects of 
DGLA upon platelet reactivity by assessing expression of platelet activation markers 
on the platelet surface via flow cytometry. This included activation of integrin αIIbβ3  
through binding of PAC-1, and exposure of PS as binding of annexin V. Integrin αIIbβ3 
activation is essential for platelet adhesion and aggregation via bidirectional 
signalling 169, whereas externalization of PS on the platelet surface allows formation 
of thrombin and a fibrin network for clot stabilization 170. As a result, I also report 
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studies aimed at investigating the effect of DGLA alone or together with aspirin on 
PAC-1 and annexin V binding. 
 As part of the above responses, platelet rapidly change their shape following 
activation,  and regulated cytoskeletal rearrangement is regarded as the main driver 
behind successful aggregation, adhesion, spreading and surface marker expression. 
Two main components of the cytoskeleton are actin and tubulin. During platelet 
activation, reorganization of actin filaments bound to myosin mediates the 
production of filopodia and lamellipodia for extensions and the display of surface 
receptors for adhesion to matrix or aggregation 171. The underlying microtubule ring 
consisting of tubulin localizes granules and plays an important role in secretion 
processes 9,10. Consequently, I also investigated the effect of DGLA on the platelet 
cytoskeleton in both resting and activated states, including during adhesion and 
spreading. Additionally, I studied the effect of LA treatment on cytoskeletal 
arrangement to gain insights into the potential effects of other PUFAs on membrane–
cytoskeleton interactions. 
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4.2 Methodology 
4.2.1 Measurement of platelet aggregation 
4.2.1.1 Optical multichannel (Optimul) platelet aggregometry assay 
4.2.1.1.1 Preparation of Optimul plates 
To prepare the plates for the Optimul assay, flat-bottom, half-area microtiter plates 
(96-wells) were pre-coated with hydrogenated gelatine in phosphate buffered saline 
(PBS) followed by the addition of increasing concentrations of AA, LA, SA, DGLA (10- 
1000μM) alone or together with ADP (3 or 10μM).  Dilutions were prepared in 
ethanol. The plates were then left in a -80°C freezer for 1 hour before being 
transferred into a freeze-dryer and left overnight. The next day, the plates  were 
vacuum-sealed and foil-packed and stored at room temperature 164.  
4.2.1.1.2 Experimental procedure 
To test aggregation of unstimulated platelets in response to different fatty acids, PRP 
was incubated with aspirin or vehicle as previously described (refer to 3.1.2 
Measurement of platelet aggregation). 40μl of PRP was then added to each well of 
the plates with PPP added into separate wells as a positive control. The plates were 
incubated on a bio shaker for 5min at 1200 rpm at 37°C.The extent of aggregation 
was measured by determination of optical density at 595nm. 
4.2.1.2 Light transmission aggregometry (LTA) 
LTA is considered the gold standard to measure platelet activity. For each test, 225μl 
PRP was added into a cuvette containing a magnetic stir bar and placed in one of 
eight channels at 37°C in a Bio/Data PAP-8E turbidimetric aggregometer at a stir 
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speed of 1200 rpm. Prior to the experiment, all channels were blanked with 225μl 
PPP plus 25μl PBS, stirred under the same conditions. Before adding the sample, PRP 
was incubated with aspirin or vehicle as previously described (refer to 3.1.2 
Measurement of platelet aggregation). Fatty acids used were AA, LA, SA and DGLA 
(1000μM) together with either ADP or TRAP-6 (1, 3 or 10μM). Dilutions were 
prepared in PBS. To study the effects of P2Y12 receptor inhibition and aspirin on 
platelet aggregation, platelets were pre-treated with aspirin or vehicle and AR-C 
66096, a P2Y12 receptor antagonist (0.3μM), for 15min. Platelets were further 
incubated with DGLA (10μM - 60μM) and then stimulated with TRAP-6 (3μM). In 
separate studies, vehicle or aspirin-treated platelets were exposed to increasing 
concentrations of AR-C 66096 (0.03μM - 30μM) for 15min before the addition of 
DGLA (3μM) or vehicle and TRAP-6 (3μM). 
 To measure aggregation, 25μl agonists were added into the samples following 
baseline measurements and the changes in light transmission then detected for 5min 
and taken to be representative of aggregation  
4.2.2 Flow cytometric assessment of platelet activation 
PRP was treated with aspirin or vehicle and exposed to DGLA (1000μM) or vehicle in 
a 96-well plate at 200 rpm, 37°C for 3min, and stimulated with TRAP-6 (3μM) at 200 
rpm, 37°C for 10min. Thrombin (1U/ml) plus collage-related peptide (CRP) (1μg/ml) 
was used as a positive control for annexin V binding. Samples were then incubated 
for 15min in the dark with Brilliant Violet anti-human CD42b together with APC anti-
human Annexin V (1:100) or FITC anti-human PAC-1 (1:20). The CD42b antibody binds 
to the GPIbα subunit and is used as a platelet marker, while annexin V binds to PS on 
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the platelet surface and PAC-1 recognizes the active form of the fibrinogen receptor 
αIIbβ3. After incubation, samples incubated for PAC-1 detection were fixed with 1% 
formalin in saline, while samples for annexin V were not fixed as this can lead to 
factitious PS externalization 172. Flow cytometry was then conducted to identify 5000 
CD42b positive events and to quantify mean fluorescence intensity values for all PAC-
1 positive events with an ACEA Novocyte 3000 flow cytometer. Annexin V-positive 
platelets were detected from individual FACS tubes via the BD LSRII flow cytometer. 
Data was analysed via Flowjo 10.4.1. 
4.2.3 immunofluorescence imaging of platelet adhesion and spreading 
To investigate adhesion and spreading of platelets, square coverslips were coated 
with fibrinogen (100µg/ml) overnight at 4°C. The next day, the cover slips were 
blocked with 1% BSA in PBS for 1h. Platelets were isolated and treated with aspirin 
or vehicle as previously described (refer to 3.1.2 Measurement of platelet 
aggregation) and diluted 1:10 in modified Tyrode's/HEPES (MTH).  Platelets were 
exposed to DGLA (1000μM) for 3min before 100µl platelet suspension was added to 
the coverslips and left to incubate for 1h at 37°C. Non-adherent platelets were 
removed by washing slides with filtered PBS 2-3 times. Slides were fixed using 0.2% 
paraformaldehyde (PFA) for 10min and washed with filtered PBS as previously 
described. Platelets were then permeabilised with 0.2% triton for 5min, washed 
again and stained with Alexa fluor-488 phalloidin (1:200) for 45min. Coverslips were 
washed with PBS, mounted with Prolong Diamond Mount on microscope slides and 
stored in the fridge. Platelets were imaged using Zeiss Super resolution LSM 710 
ELYRA PS.1 microscope under supervision of Dr. Jan Soebert at the Blizard Institute. 
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For quantification, 5 randomized images were taken per treatment and analysed via 
the ImageJ software.  
4.2.4 immunofluorescence imaging of the cytoskeleton in unstimulated or 
activated platelets 
Platelets were isolated and treated with aspirin or vehicle as previously described 
(refer to 3.1.2 Measurement of platelet aggregation). Platelets were incubated with 
eptifibatide acetate (4µg/ml), an integrin αIIbβ3 inhibitor, for 5min to prevent 
aggregation before addition of TRAP-6 (3µM) and/or DGLA (1000μM)  and incubation 
for a further 5min under stirring conditions. Platelets were then fixed by addition of 
4% PFA and incubation for 10min after which 100µl sample was added onto poly-l-
lysine coverslips in a 24-well flat-bottom plate. The plate was centrifuged at 600g for 
5min and rinsed with filtered PBS 2-3 times. The plate was then incubated with 
blocking and permeabilizing buffer (0.2% Triton, 2% donkey serum and 1% BSA) for 
45min at RT and stained with primary antibodies (Alexa-647 phalloidin (1:100) and 
mouse α-tubulin (1:200)) for 1h. After washing with filtered PBS 2-3 times, platelets 
were stained with the secondary antibody (Alexa-488 donkey, anti-mouse (1:800)) 
for 45min. Plates were washed as previously described and mounted to slides using 
Prolong Diamond Mount. Coverslips were left to dry overnight and stored in the 
fridge. Platelets were imaged using the IN Cell Analyzer 6000 and analysed for 
platelet number and morphometry using the GE IN Cell Developer software (Version 
1.9.1) under supervision of Dr. Luke Gammon at the Blizard Institute. Measurements 
were taken from 1000 platelets in randomized fields. For representative images, 
platelets were imaged using a Zeiss Super resolution LSM 710 ELYRA PS.1 microscope.  
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4.3 Results 
4.3.1 The effect of ω-6 PUFAs on platelet aggregation responses of unstimulated 
platelets measured by use of Optimul 
To test the effects of PUFAs on aggregation, unstimulated platelets were incubated 
with increasing concentrations of AA, LA, DGLA and SA. AA stimulated concentration-
dependent platelet aggregation, but neither DGLA, LA or SA had an effect. 
Aggregation in response to AA was inhibited by aspirin, whereas that to ADP or TRAP-
6 was unaffected (figure 4.1). 
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Figure 4.1 Effect of increasing ω-6 PUFAs concentrations on aggregation of unstimulated 
platelets 
ω-6 PUFAs used were arachidonic acid (AA) (A), dihomo-γ-linolenic acid (DGLA) (B), linoleic 
acid (LA) (C) and the saturated fatty acid stearic acid (SA) (D). Platelet-rich plasma incubated 
with TRAP-6 (E) and ADP (F) serve as controls. The aggregation of platelets incubated with 
aspirin (ASA; 30μM; red) or vehicle (black) was measured via the Optimul assay. Results are 
shown as mean ± SEM. AA, DGLA, LA, SA, n=7; TRAP-6, ADP, n=6. Two-way ANOVA was used 
to test for statistical difference vs. vehicle; p-value *<0.05 
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4.3.2  The effect of ω-6 PUFAs on ADP-mediated platelet aggregation measured by 
use of Optimul 
To test the effect of PUFAs on stimulated platelet aggregation, platelets were 
incubated with increasing concentrations of AA, LA, DGLA and SA and stimulated with 
3μM and 10μM ADP for 5min. AA potentiated aggregation in response to 3μM ADP 
in a concentration-dependent manner. AA caused no further increases in aggregation 
responses to 10μM ADP (figure 4.2, A). DGLA inhibited aggregation of platelets in 
response to both 3 and 10μM ADP in a concentration-dependent manner (figure 4.2, 
B), and LA significantly decreased aggregations in response to 10μM ADP (figure 4.2, 
C).  SA had no effects on aggregation (figure 4.2, D). 
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Figure 4.2 Effect of increasing ω-6 PUFAs concentrations on ADP-mediated platelet 
aggregation  
Platelet-rich plasma was stimulated with ADP (3μM or 10μM) in the presence of ω-6 
increasing concentrations of arachidonic acid (AA) (A), dihomo-γ-linolenic acid (DGLA) (B), 
linoleic acid (LA) (C) and the saturated fatty acid stearic acid (SA) (D). Aggregation was 
measured by use of the Optimul assay. Results are shown as mean ± SEM, n=8. One-way 
ANOVA and Dunnett's multiple comparisons test were used to test for statistical difference 
vs. vehicle; p value *<0.05, **<0.01, ***<0.001, ****<0.0001 
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4.3.3 The effect of ω-6 PUFAs alone and in the presence of aspirin on platelet 
aggregation measured by use of light transmission aggregometry 
In previous experiments, we showed that LA and DGLA inhibited ADP-mediated 
platelet aggregation with increasing concentrations utilizing the Optimul assay. To 
study this effect in more depth, platelets were treated with 1000μM AA, LA or DGLA, 
the concentration that showed the strongest inhibitory effect during Optimul, via 
LTA. The responses were tested following treatment with vehicle or aspirin and 
activation with ADP or TRAP-6 to analyse the effects to different treatment and 
platelet agonists. Via LTA, changes in aggregation were observed to increasing 
agonist concentrations over a time course of 5min (figure 4.3).  
 Platelets incubated with 1μM TRAP-6 (figure 4.3, B) only aggregated in the 
presence of AA. This response was completely abolished in the presence of aspirin. 
The other fatty acids had no effects. 3μM TRAP-6 (figure 4.3 D, E) induced maximal 
aggregation that was unaffected by AA but was reduced by both DGLA and LA. In the 
presence of aspirin, aggregation in response to TRAP-6 plus AA or LA was decreased, 
while aggregation in response to TRAP-6 plus DGLA was even further attenuated. 
Interestingly, 3μM TRAP-6-stimulated platelets disaggregated in the presence of 
aspirin. LA also caused platelets to disaggregate. 10μM Trap-6 (figure 4.3 F, G) 
stimulated maximal aggregation of platelets which was unaffected by any of the fatty 
acids and aspirin. 
 Similar effects were seen in platelets incubated with ADP. Aggregation in 
response to 1μM ADP (figure 4.4 B, C) was further increased when platelets were also 
treated with AA. DGLA decreased aggregation, as did aspirin alone. Aspirin also 
caused platelets to disaggregate similar to what was observed with DGLA and LA in 
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the absence of aspirin. A similar tendency was observed in experiments using 3μM 
ADP (figure 4.4 D, E), where DGLA decreased maximal aggregation and aggregates 
tended to be less stable in the presence of DGLA and LA. Even though not significant, 
it seemed that DGLA further reduced aspirin-mediated inhibition. At 10μM ADP 
(figure 4.4 F, G), DGLA and LA reduced aggregation and this effect was more potent 
in the presence of aspirin. Aggregates showed increased stability compared to 1 and 
3μM ADP. 
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Figure 4.3 Effect of ω-6 PUFAs alone or in the presence of aspirin on platelet aggregation 
in response to increasing TRAP-6 concentrations 
Representative aggregation time response traces to TRAP-6 (3μM) of platelet-rich plasma. 
The x-axis displays time in seconds and the y-axis the percentage of aggregation. Maximal 
aggregation measures the highest increase of aggregation and disaggregation the extent of 
loss of aggregation over time (A). Platelets were stimulated with TRAP-6 (1μM B, C; 3μM D, 
E; or 10μM F, G) while being exposed to arachidonic acid (AA), linoleic acid (LA) and dihomo-
γ-linolenic acid (DGLA; all 1000μM). Platelets were also incubated with either vehicle or 
aspirin (ASA, 30μM) for 30min prior to the measurement of aggregation via light transmission 
aggregometry. Percentage (A, C, E) of maximal aggregation and disaggregation (B, D, F) are 
displayed after 5min. Results are shown as mean ± SEM, n=5-7. Two-way ANOVA and 
Dunnett's multiple comparisons test were used to test for statistical difference; p value * 
<0.05, ** <0.01, *** < 0.001, ****<0.0001 
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Figure 4.4 Effect of ω-6 PUFAs alone or in the presence of aspirin on platelet aggregation 
in response to increasing ADP concentrations 
Representative aggregation time response traces to ADP (3μM) of platelet-rich plasma. The 
x-axis displays time in seconds and the y-axis the percentage of aggregation. Maximal 
aggregation measures the highest increase of aggregation and disaggregation the extent of 
loss of aggregation over time (A). Platelets were stimulated with ADP (1μM B, C; 3μM D, E; 
or 10μM F, G) while being exposed to arachidonic acid (AA), linoleic acid (LA) and dihomo-γ-
linolenic acid (DGLA; all 1000μM). Platelets were also incubated with either vehicle or aspirin 
(ASA, 30μM) for 30min prior to the measurement of aggregation via light transmission 
aggregometry. Percentage (A, C, E) of maximal aggregation and disaggregation (B, D, F) are 
displayed after 5min. Results are shown as mean ± SEM, n=5-7. Two-way ANOVA and 
Dunnett's multiple comparisons test were used to test for statistical difference; p value * 
<0.05, ** <0.01, ***< 0.001 
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4.3.4 The effect of DGLA on platelet aggregation following inhibition with aspirin 
and P2Y12-inhibitor  
To investigate the effect of DGLA in combination with aspirin or P2Y12 inhibitors on 
platelet aggregation, platelets were incubated with 0.3μM of the P2Y12 receptor 
antagonist AR-C 66096 or 30μM aspirin and further incubated with increasing 
concentrations of DGLA (vehicle, 10, 30 and 60μM; figure 4.5 A) before activation 
with TRAP-6. In control conditions, DGLA produced only weak inhibition of TRAP-6-
induced aggregation. Pre-treatment with aspirin lead to an initial decrease in 
aggregation with an additive inhibitory effect following the trace of increasing DGLA 
concentrations. However, addition of AR-C 66096 increased the potency and 
maximal inhibitory effect of DGLA (logIC50 values of DGLA for inhibition of 
aggregation to 3μM TRAP-6: vehicle, -3.2 ± 0.1; AR-C66096, -3.7 ± 0.3; aspirin, -3.1 ± 
0.1). 
 I further examined responses to low concentrations of DGLA or aspirin alone 
or as dual treatment in the presence of increasing concentrations of AR-C 66096. AR-
C 66096 caused a concentration-dependent reduction in aggregation which was 
potentiated in the presence of a low DGLA concentration (30μM), that was without 
an effect alone. Addition of aspirin further inhibited aggregation and dual treatment 
with aspirin plus DGLA dramatically abolished aggregation at minimal concentrations 
of AR-C 66096 (logIC50 values of AR-C 66096 for inhibition of aggregation to 3μM 
TRAP-6: vehicle, -6.1 ± 0.2; DGLA, -6.8 ± 0.3; aspirin, -7.6 ± 0.2; aspirin + DGLA, -8.1 ± 
0.1) (figure 4.5 B). 
Resubmitted 
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Figure 4.5 Effect of DGLA, aspirin and P2Y12 inhibition on aggregation of TRAP-6-stimulated 
platelets  
Platelet-rich plasma was pre-treated with aspirin (ASA; 30μM) or AR-C 66096 (0.3μM), then 
incubated with dihomo-γ-linolenic acid (DGLA; 10μM - 60μM) and stimulated with TRAP-6 
(3μM). Results are shown as mean ± SEM; vehicle, n=8; ASA, AR-C 66096, n=4 (A). 
Alternatively, platelets were pre-treated with ASA or DGLA (30μM) alone, or in combination, 
and then incubated with increasing concentration of AR-C 66096 (0.03μM - 30μM). Results 
are shown as mean ± SEM; vehicle, DGLA, n=6; ASA, ASA + DGLA, n=4 (B). Aggregation was 
measured by use of the light transmission aggregometry. Two-way ANOVA with Tukey's 
multiple comparisons test were used to test for statistical difference vs. vehicle (A) or the 
same treatment in the absence of DGLA (B); p value *<0.05, **<0.01, ***<0.001, 
****<0.0001 
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4.3.5 The effect of DGLA alone and in the presence of aspirin on platelet activation 
markers measured by flow cytometry  
To further assess platelet activation, I investigated binding of PAC-1, which indicates 
the active form of integrin αIIbβ3, and annexin V, which indicates PS exposure, in 
platelets pre-treated with aspirin or vehicle and incubated with DGLA via flow 
cytometry. In both cases stimulation of platelets with TRAP-6 lead to significant 
increases in PAC-1 (figure 4.6 A) and annexin V (figure 4.6 B) that were inhibited by 
DGLA. Aspirin alone did not show an effect. TRAP-6-mediated platelet activation and 
thrombin plus CRP were used as  positive controls for maximal integrin αIIbβ3 
activation and PS externalization, respectively. 
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Figure 4.6 Effect of DGLA alone or in the presence of aspirin on platelet activation markers 
assessed via flow cytometry 
Platelet-rich plasma was treated with aspirin (ASA; 30μM) or vehicle, incubated with dihomo-
γ-linolenic acid (DGLA; 1000Μm) and stimulated with TRAP-6 (3μM) or vehicle (unstim) for 
5min. Presence of platelet activation markers were assessed via flow cytometry. PAC-1 
binding for integrin αIIbβ3 activation (A) was investigated with ACEA Novocyte 3000 while 
annexin V positive events for phosphatidylserine (PS) surface exposure (B) were quantified 
via the BD LSRII flow cytometer. Results are shown as mean ± SEM for median fluorescence 
intensity as arbitrary units (AU); αIIbβ3 activation, n=3; PS exposure, n=3-4. One-way ANOVA 
with Tukey's multiple comparisons test were used to test for statistical difference; p value * 
<0.05, **<0.01 
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4.3.6 The effect of DGLA on platelet adhesion and spreading 
Platelet adhesion and spreading was imaged on fibrinogen-coated coverslips utilizing 
immunofluorescence and actin staining (figure 4.7 A). I found that while both DGLA 
and aspirin decreased the average spread area per platelet, DGLA did so to a greater 
extent and significantly decreased the number of adhered platelets (figure 4.7 B). 
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Figure 4.7 Effect of DGLA alone or in the presence of aspirin on platelet adhesion and 
spreading on immobilized fibrinogen  
Confocal microscopy images of adherent platelets stained with a fluorescent actin dye (A). 
Platelet-rich plasma was pre-treated with vehicle or aspirin (ASA; 30μM) for 30min and 
further exposed to dihomo-γ-linolenic acid (DGLA; 1000μM) for 3min. The number and cross-
sectional spread surface area of adherent platelets was quantified from five randomized 
single frame images (corresponding to the area of 65.68 x 65.68μm) (B). Results are shown 
as mean ± SEM, n=4. One-way ANOVA with Tukey's multiple comparisons test were used to 
test for statistical difference; p value **< 0.01, ***<0.001 
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4.3.7  The effect of ω-6 PUFAs on the platelet cytoskeleton 
Immunostaining and confocal microscopy were used to visualise the platelet 
cytoskeleton in unstimulated and activated platelets. I observed that exposure to 
DGLA prevented cytoskeletal alterations in response to 3µM TRAP-6 and that the 
phenotype resembled unstimulated platelets in size (covered area) and length (figure 
4.8). Interestingly, DGLA-treated platelets displayed curved elongations, quantified 
by a reduction in form factor. The density levels normalized to area of actin and 
tubulin did not change (data not shown). In contrast to DGLA, LA did not cause 
cytoskeletal rearrangement in platelets (figure 4.9).  
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Figure 4.8 Effect of DGLA alone or in the presence of aspirin on the platelet cytoskeleton 
Representative confocal microscopy images of platelets stained with a fluorescent tubulin 
(green) and actin (red) dye (A). Platelet-rich plasma was pre-treated with aspirin (ASA; 30μM) 
or vehicle for 30min and then incubated with TRAP-6 (3µM) and/or  dihomo-γ-linolenic acid 
(DGLA; 1000μM) for a further 5min. Morphometry was quantified from 1000 platelets in 
randomized fields (B). Results are shown as mean ± SEM, n=4. One-way ANOVA with Tukey's 
multiple comparisons test were used to test for statistical difference; p value ** < 0.01, 
***<0.001 
86 
 
 
Figure 4.9 Effect of LA alone or in the presence of aspirin on the platelet cytoskeleton 
Representative confocal microscopy images of platelets stained with a fluorescent tubulin 
(green) and actin (red) dye (A). Platelet-rich plasma was pre-treated with aspirin (ASA; 30μM) 
or vehicle for 30min and incubated with TRAP-6 (3µM) and/or linoleic acid (LA; 1000μM) for 
a further 5min. Morphometry was quantified from 1000 platelets in randomized fields (B). 
Results are shown as mean ± SEM, n=4. One-way ANOVA with Tukey's multiple comparisons 
test were used to test for statistical difference; p value ** < 0.01, ***<0.001 
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4.4 Discussion 
In this chapter, I have investigated the effects of ω-6 PUFAs on platelet reactivity, 
more specifically aggregation, surface marker expression, adhesion and spreading 
and cytoskeletal arrangement. In unstimulated platelets, AA was the only fatty acid 
to directly promote aggregation, an effect that was inhibited by aspirin (figure 4.1). 
It is well demonstrated that AA is a precursor for the formation of prostanoids such 
as prostaglandins and TXA2 via COX-1. Released TXA2 stimulates platelet activation 
and aggregation, explaining why application of aspirin, which inhibits COX-1, 
prevents AA-induced aggregation. SA is the most common saturated fatty acid in 
human food whereas LA is the most common ω-6 PUFAs and precursor to the of ω-
6 series of fatty acids including DGLA. Neither SA, LA or DGLA initiated aggregation in 
unstimulated platelets, which implies that DGLA is not rapidly converted into AA and 
further TXA2, most likely due to the rate-limiting activity of Δ5-desaturase, the 
enzyme responsible for the conversion of DGLA to AA 161. Indeed, it has been 
indicated that increase in DGLA results in an increase in the production of alternative 
mediators via the COX-1 and 12-LOX pathways. These mediators, namely PGE1 and 
12-HETrE, have been shown to exert anti-aggregatory effects on platelets 39,107.  
 Therefore, I exposed platelets to AA, DGLA, LA and SA in combination with 
the agonists ADP and TRAP-6 to stimulate platelet activation and aggregation. 
Aggregation was measured after 5min, so the majority of ω-6 PUFAs should still be 
available as free fatty acids and therefore substrate for eicosanoid production 127. To 
identify potential effects, I utilized Optimul that allows the simultaneous 
measurement of platelet responses to increasing concentrations of the ω-6 PUFAs 
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while being activated with 3μM or 10μM ADP (figure 4.2). I found that AA increased 
maximal aggregation, while DGLA and to some extent LA decreased aggregation, in 
concentration-dependent manners. SA was without effect on aggregation in either 
activated or unstimulated platelets, so it was excluded from further experiments. To 
my knowledge, this is the first time it has been demonstrated that LA and DGLA have 
an acute inhibitory effect on platelet aggregation, as to date, platelets have only been 
incubated with fatty acids over longer time periods. This was based on previous 
findings from other research groups that show that fatty acids, next to being directly 
converted into eicosanoids, are incorporated into the platelet membrane over time 
and that altering the membrane lipid composition also influences a variety of 
signalling pathways via changes in receptor activation and availability 142,173,174.  
 As 1000μM LA or DGLA caused the strongest inhibitory response, I decided to 
investigate these effects in more depth through the use of LTA (figure 4.3, 4.4). LTA 
is the most common method to measure platelet aggregation and allows one to 
follow the aggregation response over time. In more detail, LTA enables us to observe 
the different waves of platelet activation and corresponding aggregation and 
disaggregation responses. The primary wave of aggregation is stimulated by binding 
of the agonist (ADP or TRAP-6) to its receptor on the platelet surface, enhancing a 
variety of internal signalling pathways and the display of the activated integrin αIIbβ3 
receptor that, through binding to fibrinogen, produces platelet aggregates. During 
the second wave of aggregation, activated platelets release various mediators such 
as eicosanoids, e.g. TXA2, and their granule cargos, e.g. ADP and vWF, that enhance 
platelet activation and aggregation. Together with outside-in signalling mediated 
through binding of fibrinogen to αIIbβ3,  this feedback loop ensures stabilization of 
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the aggregates and continuous platelet activation.  
 Via LTA, we can observe changes in aggregation over time including maximal 
aggregation that can be linked to the initial activation boost and disaggregation that 
can be connected to the stability of the aggregate. In both TRAP-6 and ADP-activated 
platelets, I saw a concentration-dependent increase of aggregation reaching its 
maximum at the highest concentration of the agonist. Here, 1μM ADP already 
stimulated aggregation whereas 3μM TRAP-6 was necessary to cause an aggregatory 
response. However, ADP is generally considered a weak agonist 175 and is more 
sensitive to inhibition with aspirin. Those observations can be linked to the fact that 
TRAP-6 and ADP stimulate platelet activation via different pathways involving 
selective receptors, namely PAR1 and P2Y12/P2Y1, respectively, and highlight the 
diversity of mechanisms that can lead to platelet aggregation 176.  
 In all cases, co-incubation with AA potentiated aggregation, falling in line with 
the results observed during the Optimul assay. Complete abolishment of aggregation 
with aspirin of platelets activated with both AA and 1μM ADP shows the importance 
of additional TXA2 production from exogenous AA to promote aggregation. 
Surprisingly, aspirin-treated platelets activated with 3μm TRAP-6 aggregated less in 
the presence of AA compared to platelets without AA. This may suggest that while 
aspirin blocks COX-1, more AA is available for catalysis via alternative enzymes and 
may potentially be converted into anti-aggregatory meditators. Interestingly, LA and 
DGLA produced similar effects as aspirin, i.e. reducing maximal aggregation and, to 
some extent, causing platelets to disaggregate.  
 Both the traditional LTA and the novel Optimul assay, measure aggregation 
via changes in light transmission, however, differ in a variety of settings including 
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incubation of fatty acid (freeze-dried vs. in solution) or measurement conditions 
(static vs. stirring incubation). I measured aggregation to 3 and 10μM ADP with both 
approaches and LA and DGLA inhibited aggregation to a similar extent. This 
strengthens the hypothesis that the effect I observe is a true response to the 
inhibitory capabilities of these fatty acids. Unfortunately, limited time did not allow 
me to repeat the experiment using other agonists. However, studies performed by a 
previous lab member did demonstrate an inhibitory effect of both DGLA and LA on 
collagen-induced aggregation 148. The inhibitory effects of DGLA and LA were 
especially strong at low concentrations of TRAP-6 and ADP, whereas aggregates were 
stable at high concentrations. This implies that those PUFAs might interfere with 
aggregation potentially by reducing TXA2 and ADP release, or impaired outside-in 
signalling. It  required a strong primary stimulus to overcome the inhibitory effect of 
these fatty acids which may be beneficial  in the setting of severe injury where 
haemostasis needs to be maintained.  
 In aspirin-treated platelets, I observed that, to some degree, LA and DGLA 
further potentiated aspirin-mediated inhibition of aggregation, suggesting that the 
inhibitory effects may be independent of the COX-1 pathway. Even though PGE1 
derived from DGLA oxidised by COX-1 has been shown to inhibit platelet aggregation, 
a recent study has indicated that it is only produced in low amounts and it is 12-HETrE 
produced via 12-LOX that is responsible for inhibiting ex vivo platelet activation, 
granule secretion and thrombus formation in vivo 106. Next to production of anti-
aggregatory mediators, the inhibitory effects of DGLA may also be caused by a variety 
of other mechanisms, including stimulation of cGMP 177  or sufficient incorporation 
of the fatty acids into the lipid bilayer to cause changes in receptor function and 
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signal transduction 137,142. Additional research is necessary to gain further insights 
into the processes behind this effect.  
 In addition to aspirin, P2Y12 inhibitors are commonly used in the clinic. I 
demonstrated that both aspirin and P2Y12 blockage with AR-C 6609 reduced 
aggregation with increasing DGLA concentrations. However, the logIC50 of aspirin 
plus DGLA compared to DGLA alone was within the same range (figure 4.5 A), 
indicating that addition of aspirin did not impact the concentration of DGLA 
necessary to inhibit TRAP-6‐induced platelet aggregation to 50%. On the other hand, 
pre-treatment with AR-C66096 reduced the concentration of DGLA necessary to 
provide 50% inhibition of platelet aggregation, which demonstrates an interaction 
between DGLA and P2Y12 inhibition. Indeed, it has been indicated that PGE1 and 12-
HETrE produced by DGLA, reduce platelet reactivity by Gs-mediated signalling, thus 
increasing activity of the cAMP/PKA pathway, while P2Y12 receptor antagonists 
prevent Gi-mediated inhibition of the same pathway.  Further research in measuring 
cAMP levels or PKA activity would be beneficial to shed light on the mechanisms 
underlying the potentiating effects of DGLA together with P2Y12 inhibitors on this 
signalling cascade. I also found that addition of aspirin or DGLA produced complete 
inhibition of platelet aggregation with increasing concentrations of AR-C 66096 
(figure 4.5 B). Excitingly, dual-treatment of aspirin together with DGLA dramatically 
abolished aggregation at the lowest concentration of AR-C 66096. Again, these 
results are consistent with the idea that while aspirin may just inhibit platelet 
activation pathways dependent upon TXA2, DGLA may potentiate alternative 
inhibitory pathways similar to P2Y12 inhibition. It could also be of interest to 
investigate the interactions between low DGLA and P2Y12 antagonist concentrations 
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to potentially decrease the concentration of aspirin necessary to inhibit platelet 
aggregation.  
 Besides aggregation, I studied the expression of platelet activation markers 
and adhesion capabilities. While aspirin did not have an effect in these assays, I 
showed that DGLA inhibited PS exposure and activation of integrin αIIbβ3 (figure 4.6). 
PS is essential for thrombin production through assembly of the prothrombinase 
complex (factor Xa / factor Va) that cleaves prothrombin on the outer platelet 
membrane 178. Thrombin is not only a potent platelet agonist, but also catalyses the 
conversion of soluble fibrinogen into insoluble fibrin monomers and activates factor 
XIII that crosslinks the fibrin strands to produce a stable platelet plug 179. 
Consequently, inhibition of PS externalization by DGLA suggests interesting 
influences on secondary haemostasis. On the other hand, integrin αIIbβ3 is a receptor 
binding to vWF and fibrinogen that is essential for aggregation, therefore, reduction 
of this interaction with DGLA falls in line with my previous findings of reduced platelet 
aggregation.  
 Additionally, I was investigating the effect of ω-6 PUFAs on platelet 
cytoskeletal arrangement in unstimulated and activated platelets as well as during 
adhesion and spreading. Aspirin decreased the average spread area, however did not 
show a significant effect on the number of adhered platelets, consistent with earlier 
studies 180 (figure 4.7). On the other hand, platelet adhesion and spreading were 
nearly completely abolished in the presence of DGLA; i.e. while some platelets 
produced short filopodian protrusions, none showed full lamellipodia formation. 
Lamellipodia and filopodia formation are initiated by growing actin filaments from 
the core or shorter templates, respectively, suggesting that DGLA impairs actin 
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assembly 181. Aspirin together with DGLA did not further reduce adhesion or 
spreading compared to DGLA alone.  
 While actin is essential for platelet adhesion and spreading, the microtubule 
ring supports the platelet shape and influences granule secretions 10. In unstimulated 
platelets, I observed a clear microtubule ring around the outer margin of the platelets 
that is coiled together and rearranged when platelets were activated with TRAP-6 
(figure 4.8).  While aspirin had a limited effect on actin assembly, its effect upon the 
microtubule ring is unclear. Here I have shown that aspirin does not affect tubulin 
arrangement in activated platelets and thus platelet morphology. Interestingly, 
addition of DGLA prevented microtubule arrangement in activated platelets and the 
phenotype resembled the one in unstimulated platelets. Besides a clear microtubule 
ring, DGLA treated platelets displayed curved elongations, which, to my knowledge, 
is a unique phenotype that has not been reported before. Again, this effect was only 
seen in TRAP-6 – stimulated platelets, implying that this response is linked to platelet 
activation. In addition to reversible aggregate formation, inhibition of spreading and 
cytoskeletal arrangement by DGLA could be an indication for impaired outside-in 
signalling. Alternatively, it has previously been reported that the cytoskeleton links 
to the plasma membrane and that alteration in lipid composition might influence 
cytoskeletal organization 137. Even though I aimed to avoid incorporation of DGLA 
into the membrane via a short incubation period 127, some DGLA could be 
incorporated during coverslip preparation. To exclude effects of increased 
membrane fluidity due to increased amounts of PUFAs in the lipid membrane, 
platelets were exposed to LA under the same conditions as DGLA. LA did not prevent 
cytoskeletal arrangement in platelets, suggesting that the response is not dependent 
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upon a physicochemical change in the membrane following from an increase in 
unsaturated fatty acid (figure 4.9). While this is a promising observation, limitations 
for this experiment are that DGLA has one extra double bond in the carbon chain 
than LA which may cause a stronger effect on membrane fluidity following 
incorporation 137. However, the DGLA-mediated inhibitory effect on the cytoskeleton 
is very extensive while platelets exposed to LA looked identical to vehicle-treated 
platelets. This implies that other mechanisms might be involved. Further research 
with other PUFAs with an increased amount of double bonds, e.g. EPA or AA can 
further strengthen this hypothesis. 
 In summary, in this chapter I have shown that DGLA inhibits a variety of 
specific functions important for platelet reactivity, including aggregation, expression 
of platelet activation markers on the surface, adhesion, spreading and cytoskeletal 
rearrangement. While aspirin also reduced aggregation and adhesion, inhibition of 
PS exposure, integrin αIIbβ3 activation and cytoskeletal arrangement required 
addition of DGLA. My insights into the potentiating effects of DGLA on P2Y12 
antagonist-mediated platelet inhibition, unstable platelet aggregates suggest the 
involvement of cAMP/PKA pathways in reducing platelet function.  
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5 CHAPTER - INVESTIGATING THE EFFECT OF Ω-6 PUFAS ON 
THE PROTEOMIC RELEASATE PROFILE OF PLATELETS 
5.1 Introduction 
When platelets are activated, they release a large array of proteins that influence 
surrounding cells such as leukocytes and vascular endothelial cells 57,138. The 
responses of platelets themselves are also dependent on the releasate, as secretion 
of mediators such as vWF from α-granules and ADP from dense granules amplify 
activation signalling pathways via para- and autocrine mechanisms and strengthen 
aggregate formation. It has been shown that exposure of platelets to DGLA for 10min 
abolishes dense granule secretion induced by activation of the thrombin PAR1 
receptor. These findings are comparable to what has been observed when platelets 
are exposed to increasing concentrations of 12-HETrE, metabolized via 12-LOX from 
DGLA 138. Similarly, PGE1,  the reduced COX-1 oxidation product, has been reported 
to inhibit ATP release, marker for dense granule secretion, from platelets activated 
with calcium ionophore 182. Even though those discoveries give an interesting insight 
into changes in secretion responses following exposure to DGLA, the mechanisms 
underlying the secretion of α-granules and EVs are different to those of dense 
granules which makes it difficult to translate those outcomes to the general platelet 
release reaction 183.  
 Therefore, in this chapter I aimed to investigate the effect of ω-6 PUFAS alone 
or in the presence of aspirin on the proteomic releasate profile of platelets, which 
will help to shed light on the mechanisms underlying the functional changes observed 
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in platelets (e.g. decreased aggregation) and offer new insights into potential effects 
on the vascular system 57. I also assessed the effect of DGLA on the secretion of α- 
and dense granules via flow cytometry and luciferase-luminescence analysis, as well 
as upon the concentration and size of platelet-derived EVs using Nanoparticle Tracker 
Analysis (NTA). As platelets have to be cleared from the surrounding proteins in the 
plasma for correct measurement of the releasate, I first examined the effects of ω-6 
PUFAs on washed platelets (WPs). 
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5.2 Methodology 
5.2.1 Measurement of aggregation in washed platelets 
To obtain WPs, prostacyclin (2μg/ml) and apyrase (0.02 U/ml) were added to the PRP 
and the sample centrifuged at 2300 x g for 10min.  The supernatant was discarded, 
and the pellet re-suspended in modified Tyrode's/Hepes (MTH) buffer. Prostacyclin 
(2μg/ml) was added, the sample centrifuged, and the pellet re-suspended in MTH 
buffer. The platelet number was adjusted to a physiological concentration of 3 x 108 
platelets/ml in MTH buffer plus fibrinogen (0.2% w/v) and left to rest for 1 hour. CaCl2 
(2mM) was added 2min prior to the experiment. WP were incubated with aspirin or 
vehicle as previously described (refer to 3.2.1 Measurement of platelet aggregation) 
and aggregation measured in response to increasing concentrations of AA, LA, DGLA 
and SA (10- 1000μM) alone or in combination with ADP (3 or 10μM) utilizing Optimul 
as previously described (refer to 4.2.1 Measurement of platelet aggregation). 
Platelets incubated with U46619 and ADP served as controls for successful Optimul 
plate preparation. 
5.2.2 Measurement of the proteomic releasate profile 
This experimental set was performed during a 3-months placement at the Conway 
Institute, University College Dublin under supervision of Dr. Simone Marcone at the 
lab of Prof. Catherine Godson (figure 5.2). 
5.2.2.1 Preparation of samples  
Blood samples were collected from healthy volunteers in syringes containing 0.32% 
sodium citrate and PRP was prepared by centrifugation at 200 x g, 0 brake, for 10min 
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in a platelet function centrifuge (Bio/Data corporation). PGE1 (1μM) to inhibit platelet 
activation, was added to PRP and mixed by gently inverting the tubes. PRP was then 
centrifuged at 2000 x g for 10min at RT to obtain platelet pellets which were 
resuspended in HBSS (no Ca2+, no Mg2+). PGE1 was added and the washing process 
repeated. Platelet count was adjusted to 10.5 x 108 to provide a uniform platelet 
concentration between samples and to ensure measurable releasate levels. WPs 
were left to rest in a water bath at 37°C for 30min before addition of aspirin or vehicle 
as previously described (refer to 3.2.1 Measurement of platelet aggregation) and 
CaCl2 (2mM) for a further 30min followed by measurement of aggregation.  
5.2.2.2 Preparation of the platelet releasate  
Platelets were stimulate in the LTA in response to 1U/ml thrombin following 
incubation of WPs with vehicle, DGLA, LA and AA (10, 20 or 50μM) for 3min. 
Aggregation was measured for 6min after which part of the sample was inhibited 
with diclofenac solution (1mM), to block COX-1 activity and inhibit any further 
formation of prostanoids. This sample was retained for eicosanomics, refer to 6 
chapter – Investigating the effect of the ω-6 PUFA on eicosanoid production. The 
remaining sample was treated with a 10x protease and phosphatase inhibitor cocktail 
to protect against protein degradation. The samples were centrifuged at 10.000 x g 
for 10min at 4°C and the supernatant frozen at -80°C for storage or for further 
processing. 
5.2.2.3 Processing of released proteins 
The samples were defrosted and an equal amount of 20% W/V trichloroacetic acid 
(TCA) added.  TCA concentrates proteins and removes interfering substances such as 
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salts and detergents by strongly decreasing the pH and causing protein denaturation, 
also known as precipitation 184,185. Samples were stored for 1h on ice and then 
centrifuged at 13000 rpm for 15min at 4°C. The supernatant was removed, and the 
protein pellet dried for 30min. The pellet was resuspended in urea (8M) and the 
sample left at RT for 15min with occasionally vortexing. Urea disrupts hydrogen 
bonds between amino acids causing lysis of the sample 186. The sample was stored at 
-80°C or further processed. For protein digestion, 40μl of ammonium bicarbonate 
(200mM) and 4μl of  dithiothreitol (DTT; 100mM) were added and incubated at RT 
for 30min. Ammonium bicarbonate provides a near neutral pH and optimal salt 
composition for trypsin function 187 and DTT reduces disulfide linkages ensuring an 
open protein structure 188. Afterwards, 4μl of Iodoacetamide (200mM), that prevents 
further disulfide bond formation 189, was added and incubated at RT for 30min in the 
dark. The samples were incubated overnight at 37°C following the addition of 2.7μl 
trypsin (20μg/100μl), that breaks down proteins into smaller peptides. The next 
morning, 1μl of 100% formic acid was added that causes acidification of the sample 
and stops the digestion 190. The protein concentration was measured using nanodrop 
and adjusted to 10μg per sample. To prepare the samples for mass spectrometry, a 
C18 Zip-Tip on a p10 pipette was used to desalt and concentrate peptides. To 
equilibrate the tip, 10μl of 100% acetonitrile (ACN) was aspirated and dispensed. 
Afterwards, the tip was washed three times with 50% ACN/0.1% trifluoroacetic acid 
(TFA) followed by 0.1% TFA to ensure optimal protein binding 191. 10μl of each sample 
was aspirated and dispensed 5 times into the same tube, after which the tip was 
washed 4 times with 0.1% TFA. The peptides were eluted with 10μl of 
60%ACN/0.1%TFA for 2 times into a fresh tube and vacuum dried at 45°C. The 
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samples were then resuspended in 18μl of 0.1% formic acid and 11μl added to two 
mass spec vials for analysis. The remaining samples were stored at -80°C. 
5.2.2.4 Liquid chromatography– tandem mass spectrometry (LC – MS/MS) 
LC-MS/MS analysis was performed by Dr. Eugène Dillon, at the Mass Spectrometry 
Resource, Conway Institute, University College Dublin, Ireland. LC was performed 
utilizing a reversed-phase NanoLC UltiMate 3000 HPLC system (Thermo Scientific) 
and peptide fractions were analysed on a quadrupole Orbitrap (Q-Exactive, Thermo 
Scientific) mass spectrometer.   
 During LC, particles are physically separated based on their charge 
distribution i.e. polar or non-polar charge (figure 5.1). High-performance liquid 
chromatography (HPLC) reverse-phase systems consist of a non-polar stationary 
phase and a polar mobile phase 192. The stationary phase is a column containing silica 
particles that are linked to long-chain alkyl groups that give the column a non-polar 
character while the mobile phase consists of water mixed with polar solvents (e.g., 
methanol, isopropanol, and acetonitrile). During HPLC, the sample is mixed with the 
mobile phase and pumped through the column containing the stationary phase 
under high pressure. In this particular experiment, samples with a peptide 
concentration between 2.0-2.5μg were loaded onto C18 reversed phase columns 
(10cm length, 75µm inner diameter) with an injection volume of 5μl. Samples were 
separated at a flow rate of 250nL/min and eluted based on the chemical affinity to 
the column e.g. polar molecules prefer a polar environment and thus elute faster 
through the non-polar stationary phase 193. As part of the gradient elution system, 2 
or more solvent components with significantly different polarity are employed and 
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pumped through the system in a time-dependent manner so that the solvent polarity 
changes during compound elution. Here, the molecules were separated via a linear 
gradient elution from 2 to 95% acetonitrile containing 0.5% acetic acid in 120min. 
Gradient elution allows the faster elution of less polar molecules, thereby improving 
peak resolution194. Following particle separation based on polarity, MS measures the 
m/z of the ions and the mass spectrometer switched automatically between MS and 
MS2 acquisition in a data dependent mode. During MS, electrons are dislodged from 
the original molecules in the ion source, i.e. ionization, leading to the production of 
fragments referred to as positive-charged molecular ions and electrons without 
charge. In a quadrupole analyser, four rods, two of which are either positive or 
negative charged, build a path for travelling ions while molecules without charge are 
not detected. For each injection, the voltages applied to the quadrupole are set to a 
fixed value that changes over time and allows the filtering and detection of ions 
within a narrow range of m/z values (precursor ions) 195. After separation towards a 
specific m/z ratio, ions pass through the curved linear trap (C-trap) into the Higher 
Energy Collisional Dissociation (HCD) cell, an additional collision cell where precursor 
ions collide with nitrogen collision gas and are further fragmented by collision-
induced dissociation to product ions. The combined system of higher-energy C-trap 
dissociation allows the sequential isolation and fragmentation of the twelve most 
intense ions. Fragmented ions are then injected into the Orbitrap, a form of ion trap. 
In the Orbitrap, a voltage applied to the inner core and outer electrodes results in 
spinning of the ions. After a while, ions reach a stable circular orbit and oscillate 
radially across the Orbitrap that can be detected on the outer electrodes and related 
to the m/z ratio 196. Molecules in my study were detected throughout MS spectra of 
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m/z 350-600 with a resolution of 70,000 in MS and 17,500 in MS2. 
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5.2.2.5 Processing of proteomic data 
Following LC-MS/MS, the raw data was processed via the MaxQuant computational 
platform. Standard settings supporting label-free quantification (LFQ) of proteins and 
peptides were selected and the profile of individual peptides compared to the human 
Uniprot database. The combined data set was further examined in the Perseus 
software (version 1.6.0.7) that allows the exclusion of unnecessary or incorrect 
protein identifications by filtering for potential contaminants, only identified by site 
and reverse hits. LFQ intensity values were transformed into the log2 scale. Samples 
were grouped per treatment (e.g. vehicle vs. DGLA) and proteins were filtered for 
at least 2 valid values in the three replicates. Via normal distribution, missing 
values were imputed when close to detection level. When appropriate, ANOVA or 
student t-test were applied to identify significant changes in proteins.  
5.2.2.6 Analysis of proteomic data 
 Groups with more than 50 significant different proteins between treatments 
were analysed by the Ingenuity Pathway Analysis software (IPA; version 01.13) to 
identify enriched functional pathways. Besides IPA, several other Pathway Databases 
(PDBs) have been developed that cover a variety of different species with differences 
in pathway curation and visualization approaches. Both IPA and STRING are PDBs that 
specifically focus on protein-protein interaction 197. STRING (version 10.5) was 
utilized for network analysis of small protein alterations 198. 
 For IPA, Proteins were uploaded for up to four different treatments and 
related z-scores extracted from Perseus. Core analysis allowed the investigation of 
different areas, including canonical pathways, diseases and function, regulators, and 
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networks. I utilized the output in the disease and function section that lists enriched 
pathways, ranked by z-score against each treatment, to gain more insights into 
changes in biological functions. Here, the IPA algorithm generates biological 
networks by number of focus proteins and interconnectedness, as biological 
functions usually involve locally dense interactions of proteins, as verified via 
quantitative statistical analysis 199. In contrast to the other PDBs that utilize open 
pathway databases, IPA predicts the downstream effects on biological or disease 
processes via information stored in their own curated Ingenuity Pathways Knowledge 
Base 200. This Knowledge Base allows the modelling of highly complex interactions of 
proteins or genes specific for cell, tissue or disease type from the literature. This 
includes information gathered by expert teams from the full text of articles including 
figures and table as well as from selected third-party databases such as Gene 
Ontology (GO) and Kyoto Encyclopaedia of Genes and Genome (KEGG). All 
information is reviewed before upload into the IPA Knowledge Base and provides the 
direct link to the original literature 201. 
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Figure 5.2 Schematic illustrating the experimental workflow for platelet proteomic analysis 
washed platelets were incubated with aspirin (30µM) or vehicle for 30min, then with 
arachidonic acid (AA), dihomo-γ-linolenic acid (DGLA) or, linoleic acid (LA; all 10, 20 or 50µM) 
or vehicle for a further 3min, and then stimulated with thrombin (1U/ml). Releasates were 
collected and protein composition measured by label-free liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) with analysis by Perseus for statistical significance between 
treatments and STRING and Ingenuity Pathway Analysis software for pathway enrichment. 
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5.2.3 Flow cytometry assessment of granule secretion 
To investigate granule release, PRP was treated with aspirin or vehicle as previously 
described (refer to 3.1.2 Measurement of platelet aggregation). After treatment with 
DGLA (1000μM) or vehicle and ASA and stimulation with TRAP-6 (3μM), samples 
were then incubated for 15min in the dark with Brilliant Violet anti-human CD42b 
antibody, identifying GPIbα as a platelet marker, together with either APC anti-
human CD63 antibody, a marker for dense granule release, or APC anti-human CD62P 
(P-Selectin) antibody,  a marker for α-granule release. After incubation, samples were 
fixed with 1% formalin in saline. Flow cytometry with ACEA Novocyte 3000 was used 
to identify 5000 CD42b positive events and quantify median fluorescence intensity 
values for all CD63 or CD62P positive events.  
5.2.4 Measurement of ATP release via luciferase luminescence 
ATP release following platelet activation can be used as an indicator of dense granule 
secretion. Platelets were washed (refer to 5.2.2.1 Preparation of samples) and 
treated with aspirin or vehicle as previously described (refer to 3.1.2 Measurement 
of platelet aggregation). 45μl WPs were placed into a white 96-well flat bottom plate 
and incubated with DGLA (50μM) for 3min on the bio shaker at 350 rpm, 37°C. 
Samples were further stimulated with thrombin (1U/ml) for 5min at 1200 rpm, 37°C. 
50μl of HBSS buffer, WP alone and ATP Standard (400 pmol ATP) with 1:10 serial 
dilution, was added in duplicates into empty wells. 50μl of Chronolume luciferin-
luciferase system reagent was then added to each well and the plate incubated at 
350 rpm, 37°C for 2min. Luminescence was measured by a ClarioStar 96-well plate 
reader and ATP release determined via the relative luminescence emitted by each 
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well. Data is presented as fold change from ATP [pmol]. 
Luciferin + ATP -> Luciferyl Adenylate + inorganic phosphate [PPi] 
Luciferyl Adenylate + O2 -> Oxyluciferin + AMP + LIGHT 
5.2.5 Assessment of extracellular vesicle release 
5.2.5.1 Vesicle generation 
Platelets were washed as previously described (refer to 5.2.2.1 Preparation of 
samples) and platelet count adjusted to 3 x 108. WPs were treated with CaCl2, aspirin 
or vehicle and further exposed to DGLA (50μM). Platelets were then incubated for 
3min before being further stimulated with thrombin (1U/ml) and incubated for 2 
hours at 37°C for vesicle generation. Following incubation, samples were centrifuged 
at 1000 x g for 10min, the pellet discarded, and the supernatant spun at 1000 x g for 
10min. The new supernatant was further centrifuged at 18000 x g for 45min and the 
vesicle pellet resuspended in 100μl filtered PBS (no Ca2+ and MgCl2). Vesicles were 
frozen at -80°C. 
5.2.5.2 Nanoparticle tracker analysis of platelet-derived EVs  
 
Platelet-derived EVs were diluted 1:5 in filtered PBS. Vesicle properties were 
measured with the Nanosight NS300, that uses laser illumination (488nm) which 
scatters from a suspension of particles that are moving under Brownian motion. This 
scatter is detected and visualized by a 20x magnification microscope connected to a 
highly sensitive camera. The camera was used to record five videos of 90 seconds for 
each sample. Tubes connected to the Nanosight were flushed with PBS before being 
loaded with the sample. The NTA2.1 software, that tracks particle motion from frame 
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to frame, provided data on EV concentration in the suspension and high-resolution 
particle size distribution for individual particles. Software settings for analysis were 
set to: detection threshold, 5–10; Blur, auto; minimum expected particle size, 20 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
5.3 Results 
5.3.1 The effect of ω-6 PUFAs on aggregation of washed platelets measured by use 
of Optimul 
To investigate the effect of PUFAs on platelet aggregation in WP, WP were pre-
treated with vehicle or aspirin and treated with increasing concentrations of AA, 
DGLA, LA and SA (figure 5.3 A-D). AA, DGLA and LA stimulated concentration-
dependent platelet aggregation in WPs. AA-stimulated aggregation reached a 
plateau at 50μM while aspirin failed to inhibit aggregation at concentrations larger 
than 50μM AA (figure 5.3 A). Increase in aggregation with U46619 and ADP indicated 
that the WPs were responsive and Optimul was working (figure 5.3 E, F). 
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Figure 5.3 Effect of ω-6 PUFAs on platelet aggregation in washed platelets 
ω-6 PUFAs used were arachidonic acid (AA) (A), dihomo-γ-linolenic acid (DGLA) (B), linoleic 
acid (LA) (C) and the saturated fatty acid stearic acid (SA) (D). Washed platelets incubated 
with U46619 (E) and ADP (F) serve as controls. The aggregation of platelets incubated with 
aspirin (ASA; 30μM; red) or vehicle (black) was measured via the Optimul assay. Results are 
shown as mean ± SEM; n=7. Two-way ANOVA was used to test for statistical difference vs. 
vehicle;  p value *<0.05 
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5.3.2 The effect of ω-6 PUFAs on aggregation of washed platelets stimulated with 
ADP measured by use of Optimul  
AA potentiated aggregation in response to both 3μM and 10μM ADP at 
concentrations up 50μM, after which aggregation decreased. LA and DGLA inhibited 
aggregation of platelets in response to 10μM ADP in concentration-dependent 
manners (figure 5.4).  SA had no effect on aggregation. 
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Figure 5.4 Effect of increasing ω-6 PUFAs concentrations on aggregation of ADP-
stimulated washed platelets 
Washed platelets were stimulated with ADP (3μM or 10μM). ω-6 PUFAs used were 
arachidonic acid (AA) (A), dihomo-γ-linolenic acid (DGLA) (B), linoleic acid (LA) (C) and the 
saturated fatty acid stearic acid (SA) (D). Aggregation was measured by use of the Optimul 
assay. Results are shown as mean ± SEM, n=6. One-way ANOVA and Dunnett's multiple 
comparisons test were used to test for statistical difference vs. vehicle; p value *<0.05, 
**<0.01, ***<0.001, ****<0.0001 
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5.3.3 The effect of aspirin on the proteomic releasate profile of platelets 
Utilizing LFQ-proteomic analysis, 580 proteins were found in the platelet releasate 
from at least two out of three donors. GO term enrichment analysis utilizing STRING 
linked the proteins to the reactome ‘platelet activation, signalling and aggregation’, 
’platelet degranulation’ and ‘haemostasis’ (appendix 1). All proteins were identified 
as being present in platelets by Plateletweb 202. Statistical analysis between pre-
treatment (vehicle vs. aspirin), fatty acid treatment (AA vs. LA vs. DGLA) and different 
concentrations (vehicle vs. 10, 20, 50μM for each fatty acid) was performed in 
Perseus utilizing t-test or ANOVA as appropriate to investigate significant differences 
in protein release between groups. When comparing aspirin and vehicle-treated 
platelets, release of 166 proteins was significantly altered. Interestingly, this 
difference was not associated with treatment but with inter-subject variability as 
indicated in the heat map clustering (figure 5.5). Here, each individual (indicated as 
1, 2, 3) showed a protein releasate profile distinctly different to the other subjects 
and aspirin treatment had only a minimal effect. Changes in protein release are 
displayed by red indicating relatively increased protein release and green indicating 
relatively decreased release in the assigned heatmaps. 
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Figure 5.5 Cluster analysis of proteins significantly modulated in releasates from aspirin-
treated platelets 
Platelets were pre-treated with aspirin (ASA; 30μM) or vehicle (Veh; 0.05% ethanol/PBS) and 
stimulated with thrombin (1U/ml). For each protein the log2 (intensity) was measured in 
samples from 3 individuals (noted 1, 2, 3). Green, low release; red, high release of protein. 
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4.3.1 The effect of ω-6 PUFAs on the proteomic releasate profile of platelets 
LA or AA caused only minimal changes in thrombin-stimulated protein release (figure 
5.6 A, B). However, short exposure of platelets to DGLA caused a marked 
concentration-specific switch in the releasate profile of 30 proteins (figure 5.6 C). 
There was relatively little difference between the proteins released in the presence 
of different ω-6 PUFAs (figure 5.6 D). STRING identified no network connections, 
most likely due to the low number of altered proteins. 
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Figure 5.6 Proteomic analysis of proteins significantly modulated in releasates from 
platelets exposed to ω-6 PUFAs 
Heat-map of protein intensity following hierarchical clustering of significantly changed 
proteins in releasate from platelets stimulated with thrombin (1U/ml). For each protein the 
log2(intensity) was measured in the 3 biological replicates (noted 1, 2, 3) and is shown for 
platelets exposed to arachidonic acid (AA) (A), linoleic acid (LA) (B) or dihomo-γ-linolenic acid 
(DGLA; all 10, 20 or 50µM) (C). Green, low release; red, high release of protein. Ven diagram 
demonstrating overlap and differences of released proteins between treatment groups at 
the highest concentration (50µM) (D). 
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5.3.4 The effect of ω-6 PUFAs on the proteomic releasate profile of aspirin-treated 
platelets 
Treatment with AA or LA caused only small changes in protein release stimulated by 
thrombin (figure 5.7 A, B), whereas exposure of aspirin-treated platelets to DGLA 
caused changes in the release of 138 proteins with DGLA shifting the hierarchical 
cluster independent of concentrations (figure 5.7 C). Additionally, there was an 
increase in the number of proteins that were exclusively released with DGLA or 
common between DGLA and LA, suggesting that those ω-6 PUFAs stimulate a similar 
releasate response in the presence of aspirin (figure 5.7 D). Those responses seem to 
be dependent on addition of DGLA as DGLA alone stimulates a similar releasate 
profile as DGLA plus aspirin in contrast to aspirin alone (figure 5.8). Similarly, analysis 
of DGLA plus aspirin vs. aspirin alone demonstrated a distinct shift in releasate profile 
of 68 proteins (figure 5.11 A.), while DGLA plus aspirin vs. DGLA alone only indicated 
19 different proteins (data not shown). 
 I was further interested in investigating the potential effect on biological 
responses based on the altered protein levels. Proteins that were decreased released 
following DGLA exposure were identified by STRING as a strong cluster related to the 
GO-term ‘platelet activation’ (figure 5.9). To confirm this finding and investigate 
functional changes in more detail, I utilized IPA to predict the effects of aspirin alone 
or together with increasing concentrations of DGLA on blood cells and the vascular 
system (figure 5.10). Pathway analysis predicted a decrease in platelet functions 
(aggregation, binding and adhesion of blood platelets), inflammatory responses 
(activation of leukocytes, chemotaxis) and cell death (apoptosis, necrosis) while 
predicting an increase in vascular repair responses (angiogenesis, vasculogenesis, 
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migration and cell movement of endothelial cells) in the presence of DGLA. 
Additionally, specific cellular properties are predicted to be decreased such as 
organisation of the cytoskeleton.  
 To better understand the changes stimulated by DGLA in the presence of 
aspirin, I investigated the origin of the proteins that were differentially released with 
the highest DGLA concentration (50µM) compared to aspirin alone (figure 5.11). 
Exogenous DGLA caused a strong shift in the release of 68 proteins and from those, 
20 were decreased, including adhesion proteins (vWF, THBS1), chemokines (CXCL7) 
and immune mediators (complement factor C5). Proteins that were significantly 
different are listed in table 5.1 and categorized based on their presence in α-granules  
and EVs, validated from critical literature reviews 203–205. Most of the decreased 
proteins are enriched in α-granules. Conversely, DGLA increased the levels of 
proteins found in EVs, implying that DGLA alters secretory responses.  
 
 
 
 
120 
 
 
Figure 5.7 Proteomic analysis of proteins significantly modulated in releasates from 
aspirin-treated platelets exposed to ω-6 PUFAs 
Heat-map of protein intensity following hierarchical clustering of significantly changed 
proteins in releasates from aspirin- treated platelets stimulated with thrombin (1U/ml). For 
each protein the log2 (intensity) was measured in the 3 biological replicates (noted 1, 2, 3) 
and is shown for platelets exposed to arachidonic acid (AA) (A), linoleic acid (LA) (B) or 
dihomo-γ-linolenic acid (DGLA; all 10, 20 or 50µM) (C). Green, low release; red, high release 
of protein. Ven diagram demonstrating overlap and differences of released proteins between 
treatment groups at the highest concentration (50µM) (D). 
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Figure 5.8 Proteomic analysis of proteins significantly modulated in releasates from 
platelets exposed to aspirin and 50μM DGLA alone or as dual treatment 
Cluster analysis of proteins significantly altered in the releasates of platelets treated with 
aspirin (ASA; 30μM) or dihomo-γ-linolenic acid (DGLA; 50μM) alone or in combination before 
exposure to thrombin (1U/ml). For each protein the log2(intensity) was measured in 3 
biological replicates (noted 1, 2, 3). Green, low release; red, high release of protein 
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Figure 5.9 Interaction network of proteins that are decreased released from aspirin-treated 
platelets following exposure to DGLA 
Platelets were pre-treated with aspirin (30μM), exposed to DGLA (10, 20 and 50µM) and 
stimulated with thrombin (1U/ml) to cause a strong proteomic releasate response. Protein 
interaction of proteins that were decreased release in the presence of DGLA was evaluated 
in the STRING software and proteins indicated in red have been linked to the GO-term 
‘platelet activation’. 
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Figure 5.10 Prediction of biological processes altered by DGLA in combination with aspirin 
relative to aspirin alone via Ingenuity Pathway Analysis.  Orange, predicted activation; blue, 
predicted inhibition. ASA: aspirin 
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Figure 5.11 Proteomic analysis of proteins significantly modulated in releasates from 
aspirin-treated platelets exposed to 50μM DGLA 
Cluster analysis of proteins significantly modulated in releasate from platelets incubated with 
aspirin (ASA; 30μM) for 30min followed by dihomo-γ-linolenic acid (DGLA; 50μM) for 3min 
and then thrombin (1U/ml). For each protein the log2(intensity) was measured in the 3 
biological replicates (noted 1, 2, 3). Green, low release; red, high release of protein (A). 
Volcano plot (-log10 (p-value) versus log2 (fold change)) showing changes in 68 released 
proteins of aspirin-treated platelets alone or pre-treated with DGLA (50µM). Proteins 
considered as significantly regulated (p-value <0.05 and false discovery rate (FDR) <5%) are 
plotted in red (B). 
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Table 5.1 Characterization of proteins released from platelets treated with aspirin and 
50μM DGLA 
Statistical significance of proteins released from aspirin-treated platelets activated with 
thrombin (1U/ml) exposed to vehicle or dihomo-γ-linolenic acid (DGLA; 50μM) was 
measured and displayed via volcano plot (-log10(p-value) versus log2(fold change) (figure 
3.5). Those proteins were categorized based on their presence in α-granules and extracellular 
vesicles (EVs) validated from critical literature reviews. Corresponding IDs can be found in 
supplementary table of Maynard et al J. Thromb. Haemost. 2007a, Capriotti et al Elsevier. 
2013b, Garcia et al J. Proteome Res. 2005c.. Green: decreased proteins; red: increased 
proteins 
 
# Protein names Gene 
names 
Molecule Class Volcano plot α-
Granules
a 
EVsb 
-Log10 
(P-
value) 
Log 2 
(fold 
change) 
1 Calumenin CALU Calcium-binding 
protein 
2.78 -2.19 
 
CALU_HUMAN 
2 Immunoglobulin 
heavy constant 
gamma 1 
IGHG1 Immunoglobulin 2.45 -2.70 P01857 IGHG1_HUMAN 
3 Immunoglobulin 
heavy constant 
gamma 3 
IGHG3 Immunoglobulin 2.06 -2.22 P01860 
 
4 Immunoglobulin 
heavy constant mu 
IGHM Immunoglobulin 2.45 -1.97 P01871 
 
5 Pro-platelet basic 
protein 
CXCL7 Chemokine 2.03 -2.30 P02775 CXCL7_HUMAN 
6 Alpha-1B-
glycoprotein 
A1BG Plasma 
glycoprotein 
2.24 -1.95 P04217 
 
7 von Willebrand 
factor 
VWF Coagulation factor 2.05 -2.23 P04275 VWF_HUMAN 
8 Glia-derived nexin SERPINE2 Serine proteases 
inhibitor 
2.23 -1.34 P07093 GDN_HUMAN 
9 Thrombospondin-1 THBS1 Extracellular 
matrix protein 
2.26 -2.29 P07996 TSP1_HUMAN 
10 Serglycin SRGN Proteoglycan 1.89 -2.30 P10124 
 
11 Lysosomal protective 
protein 
CTSA Enzyme: protease 4.14 -1.56 P10619 
 
12 Clusterin CLU Complement 
protein 
2.13 -2.13 P10909 CLUS_HUMAN 
13 Zinc-alpha-2-
glycoprotein 
AZGP1 Glycoprotein 2.34 -1.83 
  
14 Proprotein 
convertase subtilisin 
PCSK6 Enzyme: protease 3.42 -2.35 
  
15 Latent-transforming 
growth factor beta-
LTBP1 Extracellular 
matrix protein 
2.23 -2.31 Q14766 LTBP1_HUMAN 
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binding protein 1 
16 Angiopoietin-1 ANGPT1 Developmental 
protein 
3.28 -2.62 Q15389 
 
17 Trem-like transcript 
1 protein 
TREML1 Transcription 
factor 
2.15 -1.85 Q86YW5 TRML1_HUMAN 
18 Platelet-derived 
growth factor D 
PDGFD Growth factor 2.14 -2.02 
  
19 Complement factor 
C5 
C5 Complement 
factor 
1.89 -2.28 P01031  
20 Sialate O-
acetylesterase 
SIAE Enzyme: 
Acetylesterase 
2.62 -2.19 
  
21 Aflatoxin B1 
aldehyde reductase 
member 2 
AKR7A2 Enzyme: 
Reductase 
2.36 2.03 O43488 ARK72_HUMAN 
22 Protein diaphanous 
homolog 1 
DIAPH1 Cytoskeletal 
protein 
4.44 2.02 O60610 DIAP1_HUMAN 
23 Src kinase-associated 
phosphoprotein 2 
SKAP2 Substrate of Src 
family kinases 
2.25 1.74 
  
24 Superoxide 
dismutase 
SOD2 Enzyme: 
superoxide 
dismutase 
2.39 1.42 
 
SODM_HUMAN 
25 Heat shock protein 
HSP 90-beta 
HSP90AB1 Chaperone 3.23 2.29309 
  
26 Glutathione S-
transferase P 
GSTP1 Enzyme: 
transferase 
2.21 2.28 
 
GSTP1_HUMAN 
27 Endoplasmic 
reticulum chaperone 
HSPA5 Chaperone 2.21 1.86 P11021 GRP78_HUMAN 
28 Heat shock cognate 
71 kDa protein 
HSPA8 Chaperone 2.03 2.64 P11142 HSP7C_HUMAN 
29 Alpha-actinin-1 ACTN1 Structural protein 1.87 2.53 P12814 ACTN1_HUMAN 
30 Macrophage 
migration inhibitory 
factor 
MIF Cytokine 2.44 2.08 
  
31 Aspartyl-tRNA 
synthetase 
DARS Enzyme: 
Synthetase 
2.48 1.26 
 
SYDC_HUMAN 
32 Ras-related protein 
Rab-6A 
RAB6A Nucleotide 
binding protein 
3.07 1.97 
  
33 Filamin-A FLNA Structural protein 2.23 2.86 P21333 FLNA_HUMAN 
34 cAMP-dependent 
protein kinase 
catalytic subunit beta 
PRKACB Serine/threonine 
kinase 
2.38 1.83 P22694 KAPCB_HUMAN 
35 Elongation factor 1-
delta 
EEF1D Elongation factor 2.31 1.68 
  
36 Serine/threonine-
protein phosphatase 
2A  
PPP2R1A Serine/threonine 
phosphatase 
2.07 1.55 
 
2AAA_HUMAN 
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37 Peptidylprolyl 
isomerase F 
precursor 
PPIF Enzyme: 
Isomerase 
1.99 2.35 
 
PPIF_HUMAN 
38 Myosin-9 MYH9 Structural protein 2.24 2.63 P35579 MYH9_HUMAN 
39 T-complex protein 1 
subunit zeta 
CCT6A Chaperone 2.68 1.78 P40227 TCPZ_HUMAN 
40 Tyrosine-protein 
kinase K 
CSK Tyrosine kinase 2.01 2.53 
 
CSK_HUMAN 
41 T-complex protein 1 
subunit epsilon 
CCT5 Chaperone 2.16 1.21963 
 
TCPE_HUMAN 
42 Isocitrate 
dehydrogenase 
IDH2 Enzyme: 
Dehydrogenase 
2.60 1.64 
 
IDHP_HUMAN 
43 T-complex protein 1 
subunit gamma 
CCT3 Chaperone 2.77 2.55 
 
TCPG_HUMAN 
44 Sulfotransferase 1A1 SULT1A1 Enzyme: 
Sulfotransferase 
2.26 1.71 
  
45 Hsc70-interacting 
protein 
ST13 Chaperone 2.14 1.99 
 
F10A1_HUMAN 
46 T-complex protein 1 
subunit theta 
CCT8 Chaperone 1.97 1.87 
 
TCPQ_HUMAN 
47 Ras-related protein 
Rab-8A  
RAB8A Transport/cargo 
protein 
3.02 1.46 
 
RAB8A_HUMAN 
48 10 kDa heat shock 
protein, 
mitochondrial 
HSPE1 Chaperone 2.17 1.88 
 
CH10_HUMAN 
49 Peptidyl-prolyl cis-
trans isomerase A 
PPIA Chaperone 2.26 2.48 P62937 PPIA_HUMAN 
50 Tubulin beta-4B 
chain 
TUBB4B Structural protein 1.95 2.21 
  
51 T-complex protein 1 
subunit beta 
CCT2 Chaperone 2.78 2.05 P78371 TCPB_HUMAN 
52 Adenylyl cyclase-
associated protein 1 
CAP1 Actin-binding 
protein 
1.96 2.80 Q01518 CAP1_HUMAN 
53 Phosphofructokinase 
(platelet specific) 
PFKP Enzyme: 
Phosphotransfera
se 
2.55 2.22 
 
K6PP_HUMAN 
54 Proteasome 
activator complex 
subunit 1 
PSME1 Proteasome 
activator complex  
3.12 2.79 
 
PSME1_HUMAN 
55 Dynactin subunit 2 DCTN2 Cofactor 3.28 2.21 
 
DCTN2_HUMAN 
56 Septin-6 SEPT6 Enzyme: GTPase 2.57 2.20 Q14141 SEPT6_HUMAN 
57 Protein disulfide-
isomerase A6 
PDIA6 Chaperone 2.18 2.70 Q15084 PDIA6_HUMAN 
58 Myosin light chain 
kinase 
MYLK Serine/threonine 
kinase 
2.58 2.31 
 
MYLK_HUMAN 
59 Neddylin NEDD8 Ubiquitin-like 2.50 1.61 
 
CAND1_HUMAN 
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protein 
60 Septin-7 SEPT7 Enzyme: GTPase 1.88 2.37 Q16181 SEPT7_HUMAN 
61 Cytosolic non-
specific dipeptidase 
CNDP2 Protease, 
unclassified 
2.72 1.86 
 
CNDP2_HUMAN 
62 GTP-binding protein 
SAR1a  
SAR1A GTPase 2.66 2.19 
 
Q9NR31c 
63 Tubulin alpha-8 
chain 
TUBA8 Structural protein 2.83 2.17 
 
TBA8_HUMAN 
64 Talin-1 TLN1  Cytoskeletal 
protein 
1.92 2.72 Q9Y490 TLN1_HUMAN 
65 Leucine-rich repeat 
flightless-interacting 
protein 2 
LRRFIP2 Transcription 
factor 
2.56 2.19 
 
LRRF2_HUMAN 
66 Septin-2 SEPT2 Enzyme: GTPase 3.04 2.15 Q15019 SEPT2_HUMAN 
67 Tropomyosin, beta  TPM4 Structural protein 2.58 1.99 
 
TPM4_HUMAN 
68 Tropomyosin 1 
(Alpha) 
TPM1 Structural protein 3.49 2.16 
 
TPM1_HUMAN 
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5.3.5 The effect of DGLA alone or in the presence of aspirin on granule secretion 
measured by the use of flow cytometry and luciferase-luminescence assay  
To confirm changes in secretion as indicated in the proteomic releasate profile based 
on literature reviews, I assessed markers for the secretion of α- and dense granules 
by the use of flow cytometry. CD62P (p-selectin), a marker for α-granule secretion, 
was increased with TRAP-6 stimulation an effect that was completely abolished by 
DGLA (figure 5.12 A, B) but unaffected by aspirin. Increasing the concentration of 
DGLA caused a concentration-dependent inhibition of CD62P expression (figure 5.12 
C). Additionally, CD63, a marker for dense granule secretion, was similarly increased 
by TRAP-6 an effect that was also abolished by DGLA (figure 5.12 D). To confirm these 
findings, I measured ATP release via a luciferase-luminescence assay (figure 5.12 E) 
which similarly demonstrated an inhibitory effect of DGLA and a lack of effect of 
aspirin. 
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Figure 5.12 Effect of DGLA alone or in the presence of aspirin on markers of granule 
secretion 
Flow cytometric analysis of expression of markers for granule secretion of PRP pre-treated 
with aspirin (ASA; 30μM) and/or dihomo-γ-linolenic acid (DGLA; 1000μM). Representative 
pseudo-colour plots and histograms for CD62P expression (A). Expression of CD62P (A, B) or 
CD63 (D) on the surface of unstimulated vehicle or TRAP-6 (3μM)-stimulated platelets for 
median fluorescence intensity (MFI). Effect of increasing DGLA concentrations (100 – 
1000μM) on CD62P expression in unstimulated or TRAP-6-stimulated platelets (C). ATP 
release measured via luminescence-based analysis of TRAP-6 (3μM)- stimulated platelets 
treated with ASA, vehicle and/or DGLA. Data is presented as relative fold change in ATP 
[pmol] (E). Results are shown as mean ± SEM for median fluorescence intensity as arbitrary 
units (AU); n=3; ATP release n=5. One-way ANOVA with Tukey's multiple comparisons test 
(B, D) or with Dunnett's multiple comparisons test (E); or two-way ANOVA with Dunnett's 
multiple comparisons test vs. vehicle or TRAP-6 vehicle vs. unstimulated vehicle (C) were 
used to test for statistical difference; p value *<0.05, **<0.01, ***<0.001, ****<0.0001. 
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5.3.6 The effect of DGLA alone or in the presence of aspirin on secretion of 
platelet-derived EVs measured by the use of Nanoparticle tracker analysis  
EVs released from platelets pre-treated with aspirin or vehicle, activated with 
thrombin and exposed to DGLA were measured via NTA. EV size was quantified on a 
particle by particle basis and concentration measured for particles/ml. There was a 
high variation in vesicle concentration within each treatment and even though here 
was a tendency for an increase with aspirin and DGLA, the difference to vehicle was 
not significant (figure 5.13 B). Additionally, there was no change in vesicle size with 
treatment (figure 5.13 C). 
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Figure 5.13 Nanoparticle Tracker analysis of extracellular vesicles derived from platelets 
treated with aspirin or DGLA alone or as dual treatment 
Washed platelets were treated with aspirin (ASA; 30μM) or vehicle and exposed to dihomo-
γ-linolenic acid (DGLA; 50μM) for 3min before stimulation with thrombin (1U/ml). Platelet-
derived EVs were detected via a high sensitivity camera that quantified EV size on a particle 
by particle basis and concentration of particles/ml from the scattered laser light (A). 
Concentration (B) and size (C) is displayed as fold change from vehicle (thrombin alone). 
Results are shown as mean ± SEM; n=7. One-way ANOVA and Dunnett's multiple 
comparisons test were used to test for statistical difference vs. vehicle. 
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5.4 Discussion 
Analysing the platelet proteome offers many advantages over common platelet 
function testing as it allows precise insights into functional alterations as well as the 
underlying mechanisms. While the global platelet proteome has a strong relevance 
for platelet characterization in disease, investigating the proteomic releasate profile 
reflects the platelet state following acute stimulus while decreasing sample 
complexity. Additionally, alteration in released proteins may predict effects on other 
cells in the surrounding microenvironment.  
 To investigate the effect of ω-6 PUFAs on the proteomic profile, an additional 
washing step was necessary to clear the platelets from surrounding plasma protein 
and to allow a precise measurement of released proteins. An important function of 
serum albumin in the blood is binding free fatty acids and facilitating their transport 
to tissues, thus decreasing free fatty acids in the blood 206. It has been shown that 
enhanced extracellular concentrations of free fatty acid can display a ‘detergent’ 
effect by disrupting the cellular plasma membrane, resulting in platelet breakdown 
130. I found that in WP free from plasma proteins, AA, LA and DGLA stimulated 
aggregation with the AA response reaching a plateau at concentrations higher than 
50μM, and that responses to concentrations of AA higher than 50μM were not 
inhibited by aspirin (figure 5.3). Additionally, AA potentiated aggregations when 
combined with ADP at concentrations up to 50μM, followed by a reduction of 
aggregation at higher AA concentrations (figure 5.4). Those findings were notably 
different to responses observed in PRP in earlier studies. Both findings in WP, i.e. 
aspirin failing to inhibit AA-stimulated aggregation and the biphasic curve at 
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concentrations higher than 50μM, could be explained by COX-independent effects 
and perhaps platelet disruption. As a result, I utilized concentrations of ω-6 PUFAs 
not higher than 50μM for the proteomics experiments to avoid nonspecific reactions. 
 For the proteomic analysis, platelets were pre-treated with aspirin or AA, LA 
or DGLA alone or in combination before being activated with a high thrombin 
concentration to stimulate a strong secretory response. Here, we observed a distinct 
individual clustering with changes in protein signature in response to aspirin for each 
donor (figure 5.5). This falls in line with previous studies investigating the proteomic 
releasate profile of a variety of anti-platelet agents such as P2Y12 antagonists and 
aspirin. Similar to my experiments, the authors observed a strong interindividual 
clustering with treatment 56. That each individual shows a distinct protein profile 
following treatment that is different to the other subjects may be useful in 
developing our insights in the effects of anti-platelet therapies on platelet function 
beyond general aggregation testing that may fail to distinguish well between 
different treatments.  
 In contrast to aspirin alone, increasing concentrations of DGLA caused 
marked changes in protein release (figure 5.6), and these changes were even more 
pronounced when platelets were pre-treated with aspirin (figure 5.7). Statistical 
comparisons between DGLA plus aspirin and DGLA or aspirin alone indicated that 
DGLA is the driver behind this altered profile (figure 5.8). Additionally, neither AA nor 
LA caused such potent effects, confirming specific effects of DGLA upon platelets. 
Even though promising, DGLA alone lead to changes in 30 proteins which was not 
enough difference compared to vehicle to study protein-protein interaction or 
predict associated biological changes in platelet function or the vasculature. 
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Conclusively, further analysis was performed on proteins altered by DGLA from 
aspirin-treated platelets. Here, proteins that showed decreased release in the 
presence of DGLA were linked to platelet activation by STRING (figure 5.9) and this 
was confirmed by IPA, which predicted inhibition of a variety of platelet-specific 
functions including aggregation and adhesion (figure 5.10). Additionally, IPA 
predicted reduction in several cellular characteristics, such as secretion of molecules 
and organization of the cytoskeleton. This analysis indicated that DGLA inhibits active 
secretion processes, as proteins whose release was decreased by DGLA compared to 
vehicle have been linked to α-granules (table 5.1, figure 5.11). This was further 
confirmed by complete abolishment of the surface receptor CD62P, which is a marker 
for α-granule release (figure 5.12 A-C). Additionally, dense granule secretion was 
inhibited by DGLA as indicated in reduction of CD63 expression and ATP release 
(figure 5.12 D, E). This adds to the hypothesis that DGLA may interfere with the 
secondary activation pathway which is linked to platelet secretion. Next to being a 
marker for degranulation, CD62P is an important adhesion receptor that binds 
leukocytes and facilitates their recruitment to the side of vascular injury 207. 
Therefore, DGLA may also directly interfere with inflammation and thrombus 
stabilization 208. 
 While decreasing granule release, DGLA may also increase the release of EVs 
that ‘bleb’ from the membrane upon platelet activation (table 5.1). EV release can 
occur spontaneously but has also been linked to disruption of the phospholipid 
membrane and attached cytoskeleton 209. A closer look at individual proteins that 
showed increased release in the presence of DGLA reveals that many of these 
proteins are required for normal organization of the cytoskeleton (e.g. CSK 15, SEPT6, 
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7, 2 11, TLN 13, TPM4, TPM1116, HSPs210) or are part of the microtubule ring (e.g. 
TUBB4B and TUBA8 9), which may be the reason why IPA predicted inhibition of 
cytoskeletal rearrangement. To further investigate the effect of DGLA on EV release, 
I quantified EV concentration and size via NTA (figure 5.13). Unfortunately, there was 
a strong variability in EV quantity and quality of the samples within each treatment. 
Specifically, samples treated with aspirin showed a slight increase in EV 
concentrations which is in contrast to previous findings showing that aspirin reduces 
EV release from platelets 211. This suggests that an error in sample preparation might 
have interfered with the EV number. Besides concentration, vesicle size did not alter 
between treatments.  
 In addition to several platelet-specific effects, IPA predicted DGLA would 
cause alterations of functional pathways in the vascular system leading to reduced 
inflammatory responses, cell death and increased vascular repair (figure 5.10). 
Indeed, increasing evidence indicates that platelets have a key role in mediating 
apoptosis and tissue repair 212, and that reduction in the release of granule proteins 
(e.g. C5, APP, CCL5, F5, FN1, PLG, PROS1, THBS1, TGFB1) is linked to reduced 
inflammation.  
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6 CHAPTER - INVESTIGATING THE EFFECT OF Ω-6 PUFAS ON 
EICOSANOID PRODUCTION 
6.1 Introduction 
Eicosanoids play an important role in platelet function due to their potent abilities to 
stimulate signalling pathways by binding to receptors on the platelet surface. In 
platelets, AA plays a key regulatory role as it is rapidly released following platelet 
activation and is metabolized into a large array of eicosanoids via several enzymes 
such as COX-1, 12-LOX and CYP450. Eicosanoid production is highly dynamic and can 
be altered by changes in enzyme activity, such as selectively blocking COX-1 with 
aspirin, or the availability of substrates, such as changes in the PUFA pool leading to 
the production of additional eicosanoids. In studies reported in this chapter, I was 
especially interested in how the eicosanoid profile from platelets changes following 
exposure to the ω-6 PUFAs AA, DGLA and LA, with or without the addition of aspirin. 
The most studied DGLA-derived eicosanoids from platelets are PGE1 and 12-HETrE 
that are produced via COX-1 and 12-LOX, respectively, and have been shown to 
produce anti-aggregatory effects 39,213,214. However, limited research has also 
indicated the production of other mediators from DGLA such as alternative series 1 
prostaglandins PGD1 215 and PGF1α 216 as well as 15-HETrE 161 and 8-HETrE. The 
production of 8-HETrE from DGLA has only been shown in one publication from 1976 
employing rabbit leucocytes 146. To investigate if platelets can produce those 
eicosanoids and how aspirin might change the eicosanoid profile in combination with 
ω-6 PUFAs, eicosanomic studies were conducted through LC-MS/MS analysis of 
platelet releasates and lysate. 
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6.2 Methodology 
6.2.1 General lipidomics from platelet releasate 
Platelets were treated and activated as previously described (refer to 5.2.2.1 
Preparation of samples) and the releasates frozen at -80°C. The releasate was 
aliquoted and one part of the samples was used for proteomic analysis ( 5 chapter – 
Investigating the effect of the ω-6 PUFAs on the proteomic releasate profile of 
platelets), and the other part of the sample was utilized for general lipidomic analysis 
by Dr. Matthew L. Edin at The National Institute of Environmental Health Science, 
North Carolina, USA. The LC-MS/MS protocol was executed as follows: ‘’3ng of d9-
PGE2, d11-11,12-DHET, d11-11,12-EET were used as internal standards and added in 
equal amounts with 0.1% acetic acid in 5% methanol. Samples were extracted with 
2ml ethyl acetate containing 6μl 30% glycerol in methanol via liquid : liquid 
extraction. Ethyl acetate was evaporated using vacuum centrifugation, the samples 
exposed to argon and stored at-80°C. 50μl of 30% ethanol was added to the sample 
and analysed in duplicate via 10μl injections. Online liquid chromatography from 
reconstituted samples was performed utilizing an Agilent 1200 Series capillary HPLC 
Separations with a HaloC18 column (2.7mm, 10062.1mm). The Mobile phase A 
consisted of 85:15:0.1 water: acetonitrile: acetic acid. Mobile Phase B was 70:30.01 
acetonitrile: methanol: acetic acid. Molecules were separated at a flow rate of 
400μl/min via gradient elution involving different concentration of mobile phase B 
throughout 19min. At 0 min mobile phase B percentage was 20%, 0-5min to 40%, 5-
7min to 55%, 7-13min to 64% and 13-19min to 100% B at a flowrate at 550μl/min. 
Mass spectrometry was performed utilizing an MDS Sciex API 30000 with a 
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TurbolonSpray source. The Turbo desolvation gas was heated to 425°C at a flow rate 
of 6L/min. Molecules were detected via negative ion electrospray ionization tandem 
mass spectrometry with multiple reaction monitoring. Data quantification was 
performed comparing ratios of relative responses for each analyte/internal standard 
to standard curves of analyte with the Analyst 1.5.1 software.’’ 
6.2.1.1 Analysis of lipid mediator production 
To explore the correlation of the broad spectrum of eicosanoids to different 
treatment and ω-6 PUFA concentrations, the data was processed via Partek Flow 
(version 6/6) for hierarchical clustering and Partek Genomics Suite for principle 
component analysis (PCA). In both cases, fold change to vehicle was quantified for 
each eicosanoid before being uploaded into the software for visualization. The 
heatmap for hierarchical clustering was normalized to standardised expression 
values with mean of 0 and standard deviation of 1. Statistical analysis for levels of 
individual eicosanoids was performed using Graphpad Prism.  
6.2.2 Targeted lipidomics in platelets 
To perform target lipidomics on platelet lysate, platelets were treated with aspirin 
and/or DGLA and activated as previously described (refer to 5.2.2.1 Preparation of 
samples). Following incubation with thrombin (1 U/ml) for 5min, platelets were snap 
frozen with dry ice and stored at -80°C until further processing. LC-MS/MS analysis 
was performed by the Lipid Mediator Core at William Harvey Research Institute, 
London, UK. 
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6.3 Results 
6.3.1 The effect of ω-6 PUFAs on the lipid releasate profile of platelets 
To study the effect on eicosanoid production, platelets were treated with aspirin or 
vehicle and/or AA, DGLA and LA and stimulated with thrombin. To visualize the 
correlation of relative changes in released eicosanoids, I utilized hierarchical 
clustering via heatmap and PCA. The heatmap indicates relative changes in released 
eicosanoids with samples shown on rows and eicosanoids on columns. Addition of 
LA led to a clear clustering of selected mediators, namely 13-HODE, 9-HODE and 9-
10-EpOME, 12-13 EpOME as well as their stable epoxide hydrolase products 9,10-
DHOME and 12,13-DHOME, respectively (figure 6.1). Alternatively, addition of AA 
was linked to a clustering of COX-1 mediators (TXB2, PGE2, PGD2, PGF2α) that were 
decreased in the presence of aspirin. Additionally, AA caused increases in the levels 
of 11-HETE, 15-HETE, 19-HETE, 12-HETE, 5-6-EET, 11-12-EET, 14-14-EET and their 
stable products 5-6-DHET, 11-12- DHET, 14-14- DHET.  
 This pattern was also reflected in PCA, that displays correlation of variables. 
Here, the axes describe the variations between data as principle components (PC), 
with PC1 indicating the strongest difference between data points. In the vehicle-
treated group, we identified a strong correlation of each individual fatty acid with 
increasing concentrations as each condition is clustered together (figure 6.2 A).  Here, 
the highest variation can be found between AA and LA treatment that run along PC1 
at the PCA plot. This can be attributed to the production of specific AA and LA-derived 
metabolites. LA, 13-HODE and 9-HODE are clustered together, indicating that 
increase in LA relates closely to an increase in both eicosanoids. Similarly, AA-derived 
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eicosanoids are clustered together and are therefore clearly linked to an increase in 
exogenous AA. DGLA did not alter the production of those eicosanoids which can be 
seen in the small clustering in the plot centre. Addition of aspirin decreased the 
variance in the data set of mediators derived from each fatty acid, indicated by a 
decrease in the PC percentage e.g. PC1 vehicle 64.1%, aspirin 60%. 
 To investigate changes in AA-derived mediators following from exposure to 
different ω-6 PUFAs in more detail, I studied the alteration in levels of each individual 
eicosanoid (figure 6.3). As expected, exogenous AA stimulated a concentration-
dependent increase in all selected mediators and addition of aspirin completely 
abolished the release of AA-derived TXB2 and prostaglandins. There was, however, 
still an increase in 11,12- and 14,15-EET + DHET, 11-HETE, 15-HETE, LXA4 and LXB4. 
AA also increased the levels of 12-HETE, a response that was unaffected by aspirin. 
Addition of DGLA increased AA in a concentration-dependent manner, an effect that 
was slightly reduced by aspirin. Increasing DGLA concentrations did not affect the 
production of most eicosanoids but did cause a slight reduction in 11-HETE and PGD2. 
In the presence of aspirin, DGLA increased the levels of 14,15- EET + DHET. Addition 
of LA reduced AA and the release of all AA-derived prostaglandins, TXB2, 11-HETE and 
15-HETE. Conversely, LA caused concentration-dependent increases in the levels of 
13-HODE, 9-HODE, that were reduced by aspirin, and 9,10-EpOME and 12,13 EpOME 
as well as their stable epoxide hydrolase products 9,10-DHOME and 12,13-DHOME 
(figure 6.4). Neither AA nor DGLA influenced the release of these mediators.   
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Figure 6.1 Cluster analysis of selected eicosanoids modulated in releasates from platelets 
exposed to aspirin or ω-6 PUFAs alone or as dual treatment 
Hierarchical clustering of eicosanoids detected in releasates from platelets pre-treated with 
aspirin (ASA; 30μM) or vehicle (Veh; 0.05% ethanol/PBS) and exposed to arachidonic acid 
(AA), linoleic acid (LA) or dihomo-γ-linolenic acid (DGLA; all 10, 20 and 50μM) for 3min before 
stimulation with thrombin (1U/ml). Eicosanoids were measured in 4 biological replicates 
using liquid chromatography tandem mass spectrometry analysis. The heatmap is based on 
standardized expression levels (mean of 0, standard deviation of 1) with blue indicating low 
and red indicating high levels of each individual eicosanoid. 
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Figure 6.2 Principle component analysis performed on eicosanoids identified from 
platelets exposed to ω-6 PUFAs with or without aspirin 
Variance of eicosanoids measured in releasates from platelets exposed to arachidonic acid 
(AA), linoleic acid (LA) or dihomo-γ-linolenic acid (DGLA; 10, 20 or 50μM), detected via liquid 
chromatography tandem mass spectrometry analysis from 4 biological replicates. Platelets 
were pre-treated with vehicle (0.05% ethanol/PBS) (A) or aspirin (ASA, 30μM) (B). 
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Figure 6.3 Effect of increasing ω-6 PUFAs concentrations on the release of arachidonic acid-
derived eicosanoids 
Eicosanoids were measured in releasates from platelets pre-treated with  aspirin (ASA; 
30μM) or vehicle (Veh; 0.05% ethanol/PBS) and exposed to arachidonic acid (AA), dihomo-γ-
linolenic acid (DGLA) or linoleic acid (LA; all 10, 20 or 50μM) for 3min. Platelets were 
stimulated with thrombin (1U/ml) and eicosanoids detected using liquid chromatography 
tandem mass spectrometry analysis. Results are shown as mean ± SEM; n=4. A two-way 
ANOVA with Dunnett's multiple comparisons test was applied for significance testing vs. 
vehicle within each treatment, and with Holm-Sidak’s multiple comparisons test for vehicle 
vs. aspirin. P value *<0.05, **<0.01, ***<0.001, ****<0.0001. PG, prostaglandin; HETE, 
hydroxyeicosatetraenoic acid; HpETE, hydroperoxyeicosatetraenoic acid; TX, thromboxane; 
EET, epoxyeicosatrienoic acids; DHET, dihydroxyeicosatrienoic acid.  
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Figure 6.4 Effect of increasing ω-6 PUFAs concentrations on the release of linoleic acid-
derived eicosanoids. 
Eicosanoids were measured in releasates from platelets pre-treated with  aspirin (ASA; 
30μM) or vehicle (Veh; 0.05% ethanol/PBS) and exposed to arachidonic acid (AA), dihomo-γ-
linolenic acid (DGLA) or linoleic acid (LA; 10, 20 or 50μM) for 3min. Platelets were stimulated 
with thrombin (1U/ml) and eicosanoids detected using liquid chromatography tandem mass 
spectrometry analysis. Results are shown as mean ± SEM; n=4. A two-way ANOVA with 
Dunnett's multiple comparisons test was applied for significance testing vs. vehicle within 
each treatment, and with Holms-Sidak's multiple comparisons test for vehicle vs. aspirin. P 
value *<0.05, **<0.01, ***<0.001, ****<0.0001. EpOMEs, epoxyoctadacamonoenoic acids; 
DiHOMEs, dihydroxyoctadecenoic acids; HODE, hydroxyoctadecadienoic acids. 
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6.3.2 The effect of DGLA on targeted eicosanoid profiling of platelets 
The production of specific DGLA-derived eicosanoids, i.e. PGE1, PGD1, PGF1α, 12-
HETrE, 15-HETrE and 8-HETrE, by platelets, pre-treated with vehicle or aspirin, was 
investigated in samples from four donors. Platelets were exposed to DGLA and 
stimulated with high thrombin concentration in the LTA and no significant change in 
aggregation was observed (aggregation graph in appendix 2).  Eicosanoids from lysed 
samples were investigated and PCA showed a clear clustering of treatment with 
DGLA while there were no differences in the presence of vehicle or aspirin alone 
(figure 6.5 A). While all mediators were increased with DGLA compared to vehicle, 
dual treatment with aspirin lead to a reduction, however, not complete inhibition of 
PGD1, PGE1 and PGF1α. 12-HETrE, 15-HETrE and 8-HETrE were unaffected by aspirin 
(figure 6.5 B). TXB2 and PGE2 production were measured as controls (appendix 3). 
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Figure 6.5 Production of selected eicosanoids from platelets exposed to DGLA alone or in 
combination with aspirin 
Eicosanoids were measured in lysate from platelets pre-treated with aspirin (ASA; 30μM) or 
vehicle and exposed to dihomo-γ-linolenic acid (DGLA; 1000μM) for 3min. Platelets were 
stimulated with thrombin (1U/ml) and eicosanoids detected using liquid chromatography 
tandem mass spectrometry analysis. Principal Component Analysis (A) and concentration of 
individual eicosanoids (B) following treatment with DGLA or ASA alone or as dual treatment 
are indicated for prostaglandin (PG)D1, E1, F1, 12-, 15-, 8- hydroxyeicosatetrienoic acid 
(HETrE). One-way ANOVA and Tukey's multiple comparisons test were used to test for 
statistical difference; p value * <0.05, ** <0.01, *** p< 0.001, ****p<0.0001. 
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6.4 Discussion 
In this chapter, I report my investigations into the effects of ω-6 PUFAs on the 
production of eicosanoids from platelets activated with thrombin, as PUFAs can be 
utilized for eicosanoid production by enzymes such as COX-1, 12-LOX and CYP450. 
Following platelet activation, fatty acids, including AA, are cleaved and released from 
the phospholipid membrane. Of the various available fatty acids, AA is the most 
important one in platelet function with a complex system of balanced AA-derived 
eicosanoids produced by platelets being central to the regulation of a variety of 
physiological and pathological processes. 
 As expected, exposure of platelets to exogenous AA produced a 
concentration-dependent increase in the levels of multiple mediators, including 
eicosanoids derived from COX-1 (TXB2, PGE2, PGD2, PGF2α), 12-LOX (12-HETE) and 
CYP450 (5-6-EET, 11-12-EET, 14-14-EET and their stable products 5-6-DHET, 11-12- 
DHET, 14-14- DHET). Pre-treatment with aspirin abolished the production of all 
prostanoids, indicating complete inhibition of COX-1 (figure 6.3). It could have been 
expected that inhibition of COX-1 would divert AA as a substrate towards 12-LOX and 
CYP450 pathways, leading to an increase in 12-HETE and EETs, respectively. However, 
I detected no changes in levels of these mediators following addition of aspirin, falling 
in line with what has been found in measurements of global eicosanoid levels in 
serum after aspirin treatment 217. On the contrary, the levels of 11,12- and 14,15-EET 
+ DHET, both anti-aggregatory eicosanoids 218 (figure 6.6 A), were reduced by aspirin 
treatment (figure 6.3 H, I). Production of those epoxides has been commonly linked 
to CYP450, but my data indicates an involvement of COX-1 in platelets. 11-HETE and 
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15-HETE have also been linked to COX-1 activity 38 and a reduction in levels with 
aspirin in my study confirms those findings (figure 6.3 K, L). That there is still a 
production of 11- and 15-HETE with aspirin treatment indicates that alternative 
pathways might be involved. While 11-HETE has been associated with obesity 219 and 
15-HETE is involved in angiogenesis 220, tumour growth and atherosclerosis 221, none 
of these mediators have shown to directly influence platelet aggregation (figure 6.6 
A).   
 Administration of exogenous AA also led to significant increases in the levels 
of LXA4 and LXB4 (figure 6.3 M, N). This is especially interesting as it has been shown 
in previous studies from Charles Serhan’s lab dating back to 1990, that platelets are 
unable to produce LXs directly from AA and require intermediate metabolites or 
additional granulocytes for the production of those mediators 222. While the effects 
of LXs on platelet function are unclear (figure 6.6 A), LXs are known for their potent 
anti-inflammatory and pro-resolving functions 223 and several pathways leading to LX 
production have been identified that require transcellular mechanisms (refer to 
chapter 1.1.3.1.2 Transcellular production). During the first route, 15-LOX converts 
AA into 15-HPETE, that is subsequently converted into LXs by 5-LOX. 15-LOX is mainly 
found in inflammatory and epithelial cells 224, however limited evidence in the 
literature 225 as well as increase in the levels of  15-HETE (the reduced product of 15-
HPETE 226) in my samples implies the presence of a 15-LOX activity in platelets. 
 Through a second pathway, leukocytes convert AA to LTA4 via 5-LOX, and LTA4 
is further utilized by 12-LOX in platelets to produce LXA4 and LXB4. It has previously 
been reported that platelets lack 5-LOX 227 and in my samples products dependent 
upon the activity of the 5-LOX enzyme, namely 8-HETE, 5-HETE and LTs produced 
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from LTA4 (LTB4, LTC4, LTD4 and LTE4) 228, were below detection level (data not 
shown). This implies that 5-LOX is not present and confirms my samples as consisting 
of pure platelet populations without leukocyte contamination. As all known 
pathways involved in LX production of platelets to date require transcellular 
mechanisms and evidence against LX production from a pure platelet population 
without LTA4 is very strong,  an explanation for my results may be that there was a 
systematic peak-picking error during the LC-MS/MS leading to the apparent 
detection of LXA4 and LXB4. Further research is necessary to confirm those findings. 
 Addition of LA to platelets led to a decrease in AA and most AA-derived 
mediators, most likely because LA is further up the metabolic chain and produces its 
own eicosanoids via COX-1 and CYP450 (figure 6.3). 12-LOX is not able to utilize LA as 
a substrate due to the position side of the active CH2 methylene, the centre for LOX 
catalysis, which could explain why the production of 12-HETE is unaffected by 
addition of LA 138 (figure 6.3 J). In addition to production of LA-derived eicosanoids, 
measuring how much DGLA is produced from LA and how much is further converted 
into DGLA-derived mediators would offer increased insights into potential saturation 
of enzymes linked to decreased downstream products of AA. Alternatively, LA caused 
an increase in the levels of 13-HODE, 9-HODE and 9,10-EpOME, 12,13 EpOME as well 
as their stable epoxide hydrolase products 9,10-DHOME and 12,13-DHOME (figure 
6.4). Neither AA or DGLA influenced EpOME or DHOME production, however 
significance analysis indicated a significant reduction in EpOME levels at high LA 
concentrations in the presence of aspirin. While CYP450 activity has been linked to 
the production of EpOME from LA, the effect of aspirin indicates an influence of COX-
1. Those epoxide products are generally considered pro-inflammatory, however, an 
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acute inflammation model has been associated with a decrease in 9,10-EpOME and 
mice with a knockout of sEH, the enzyme responsible for the conversion of EpOMEs 
to DHOMEs, showed decreased inflammation and enhanced resolution responses 
together with an increase in the levels of epoxides 46. The levels of 9- and 13-HODE 
were also reduced by aspirin and sustained production of 13-HODE suggests the 
involvement of alternative pathways, potentially via 15-LOX 229 (figure 6.4 F, G). The 
effects of HODE on platelets have been extensively studied and linked to platelet 
survival 230, as well as decreased platelet adhesion and aggregation 231 (figure 6.6 B). 
In particular, 13-HODE is a potent regulator of platelet functionality via its ability to 
decrease the production of TXA2 and increase the production of 12-HETE, which 
correlates with inhibition of platelet aggregation 33,156 . 
 Incubation of platelets with DGLA had no effect on the production of AA-
derived mediators but did cause an increase in AA. This could be explained by DGLA 
replacing AA in the platelet membrane resulting in increased AA release 232, or by the 
activity of Δ5-desaturase, responsible for the conversion of DGLA to AA 92,150. In 
either case, the levels of free AA seem insufficient to cause an increase in the 
formation of AA-derived eicosanoids. 
 As DGLA did not influence the production of mediators derived from AA, I was 
interested to investigate the production of DGLA-derived eicosanoids that have been 
previously mentioned in the literature. DGLA did not reduce aggregation of platelets 
in response to 1U/ml thrombin, most likely because it was not strong enough to 
overcome the strong aggregatory response to this agonist (appendix 2). It is widely 
understood that platelets can convert DGLA into PGE1, PGD1 and 12-HETrE, however, 
here I report for the first time that platelets also produce PGF1α, 15-HETrE and 8-
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HETrE (figure 6.5). Increase in the levels of DGLA-derived eicosanoids despite 
unaltered levels of AA-derived eicosanoids with DGLA treatment in my previous 
experiments (figure 6.3) supports the theory that sufficient enzymes are available to 
avoid substrate competition. Besides being metabolized via the enzymatic route, AA 
can be converted into bioactive mediators such as HETEs non-enzymatically following 
from the actions of reactive oxygen species (ROS) 233. CYP450, LOX and COX stereo-
specifically insert oxygen in the fatty acid chain  generating oxygenated products with 
specific chirality of the hydroxyl group. Whether a left- or right-handed enantiomer 
is produced depends on the enzyme; for example, LOX generates 15(S)-HETE, 
whereas COX synthesizes 15(R)-HETE and auto-oxidation forms a racemic mixture 
with equal amounts of the two chiral molecules. CYP450 also forms predominantly 
products in R-configuration. To minimize the risk of auto-oxidation, and so the 
generation of misleading results, sample preparation needs to occur fast and purity 
of the PUFAs should be routinely monitored. In this study, I aimed to prevent 
autoxidation of the ω-6 PUFAs by storing them in ethanol under inert gaseous 
nitrogen 234. Further, high sensitivity detection methods can allow the separation of 
individual enantiomeric pairs and thus differentiation between non-enzymatic and 
enzymatic products. Unfortunately, chiral detection is generally not included into 
common LC-MS/MS, therefore I cannot exclude partial non-enzymatic formation of 
the measured HETrE products from DGLA. However, in other reports DGLA failed to 
inhibit platelet aggregation in mice lacking 12-LOX and aggregation was only 
inhibited when 12-HETrE was added, which suggest that 12-LOX is required for 12-
HETrE production and potentially the other HETrE isoforms 235. 
 Surprising for me was that aspirin did not completely inhibit the production 
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of prostaglandins from DGLA. One hypothesis to explain this could be that DGLA 
might bind to a different catalytic side than AA. However, it has been reported that 
LA, DGLA and AA show a similar conformational trend and bind to the same binding 
side 236, i.e. the Ser-530 residue that is acetylated by aspirin and thereby results in 
complete activity loss of COX-1 237. This may indicate that other enzymes are 
responsible for the production of these prostaglandins and further investigations are 
necessary to shed light into what these alternative pathways might be. Alternatively, 
TXB2 and PGE2, that were measured as controls, showed surprisingly low levels in the 
vehicle group (appendix 3). Especially when comparing the levels of those 
prostanoids to those in platelet releasates from previous experiments (figure 6.3 B, 
D); i.e. TXB2 and PGE2 from platelet lysates were 30-60 times less in this experimental 
set than measured in platelet releasates. It can be expected that the eicosanoid 
concentrations in releasate and lysate are similar, as eicosanoids are typically 
synthesized as required and released immediately after and not stored within the cell 
238; i.e. they would be present in both the full cell lysate and the cell releasate as part 
of the supernatant. Although TXB2 and PGE2 concentrations were measured below 
expected levels, levels of aspirin-treated samples of the DGLA-prostaglandins are 
above expectation, which makes it difficult to link loss in eicosanoids or similar errors 
during sample preparation to those unexpected measurements. This, together with 
low variations between individuals in those samples, might suggest a potential fault 
in the LC-MS/MS quantification and needs to be further investigated. 
 Several studies have focussed on the roles of PGE1 and 12-HETrE in 
cardiovascular disease and shown that both mediators exert anti-thrombotic 
properties through binding to GPCRs on the platelet surface 138,158,159. 12-HETrE has 
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been indicated as the most potent mediator of these two 158 and has been shown to 
exhibit strong anti-aggregatory, vasodilating and angiogenic properties 221. These 
findings imply that production of both mediators in the presence of aspirin might 
lead to potentiated inhibition of platelet function and improved anti-thrombotic 
effects 157,158. Only a small amount of research has been conducted on the other 
series-1 prostaglandins and HETrEs and their biological activities are not well 
characterised. From both prostaglandins, only PGD1 has been studied with regard to 
platelet function and shown to inhibit platelet aggregation 239,240 while both PGD1 
and PGF1α have been shown to constrict airways in a canine model 241. Furthermore, 
only one report could be identified that attributed 8-HETrE with anti-inflammatory 
properties while 15-HETrE has been linked to reduced inflammation, blood pressure 
and tumour cell proliferation 161,242. Additionally, 15-HETrE inhibits platelet 
aggregation at high concentrations 33 (figure 6.6 C). 
 To summarize, the shift in eicosanoid balance following from an increase in 
anti-aggregatory DGLA-derived eicosanoids could well explain the inhibition in a 
variety of platelet responses I observed in earlier studies examining the effects of 
DGLA in the absence and presence of aspirin. To further assess these responses, it is 
important to refine the analytical tools to measure these products and to increase 
our insight into the characteristics of novel eicosanoids such as 8-HETrE and PGF1α. 
This is especially important in the context of cytoskeletal rearrangement and granule 
secretion, as these functions were uniquely inhibited by DGLA. 
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Figure 6.6 Documented effects of ω-6 PUFA derived eicosanoids on platelet aggregation 
 
Eicosanoids derived from arachidonic acid (A), linoleic acid (B) and dihomo-γ-linolenic acid 
(C) and their documented effects on platelet aggregation. For literature references refer to 
text. HETrE, hydroxyeicosatetrienoic acid; EpOMEs, epoxyoctadacamonoenoic acids; 
DiHOMEs, dihydroxyoctadecenoic acids; HODE, hydroxyoctadecadienoic acids PG, 
prostaglandin; HETE, hydroxyeicosatetraenoic acid; HpETE, hydroperoxyeicosatetraenoic 
acid; TX, thromboxane; EET, epoxyeicosatrienoic acids; DHET, dihydroxyeicosatrienoic acid; 
LXA, lipoxin A. 
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7 CHAPTER - GENERAL DISCUSSION 
While platelets are essential for the process of haemostasis, inappropriate 
platelet activation is the underlying mechanism for atherothrombosis and 
subsequently for cardiovascular pathologies such as stroke or myocardial infarction 
2. When platelets are activated, they alter their cytoskeleton leading to secretion of 
granule-derived bioactive mediators and exposure of receptors on the platelet 
surface. Within seconds, platelets display an enhanced procoagulant and adhesive 
profile resulting in the formation of platelet-platelet aggregates through interaction 
with factors of the coagulation cascade, platelet-leukocyte aggregates via p-selectin 
expression and adhesion to the site of vascular injury 3. Throughout all these 
processes, activation of internal signalling pathways leads to increase in Ca2+, 
activation of a variety of kinases and release of PUFAs such as AA from the 
phospholipid membrane that are metabolised into eicosanoids and further enhance 
platelet activation 31. Eicosanoid production is highly dynamic and many factors, such 
as substrate or enzyme availability, can modulate eicosanoid synthesis and thus 
platelet reactivity.  
For many years, research has highlighted the cardioprotective properties of 
PUFAs, that can be utilized by platelets for the production of alternative eicosanoids 
243. The ω-6 PUFA DGLA shows many beneficial effects as it successfully inhibits 
human platelet aggregation both directly 148 and when supplied as a dietary 
supplement 109. It also reduces atherosclerotic risk 105 and thrombus formation 106 
without increasing bleeding in mice models. Those effects of DGLA have commonly 
been attributed to its metabolism to PGE1 via COX-1 and to 12-HETrE via 12-LOX 
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39,213,214. Of the two mediators 12-HETrE is of greater interest, as 12-LOX catalyses 
DGLA in preference to AA and with a faster turnover 39. Furthermore, 12-LOX is 
essential for DGLA to reduce thrombosis in mice 106. The effects of DGLA are 
especially interesting as aspirin, commonly used together with P2Y12 antagonists in 
the clinic for treatment of cardiovascular pathologies, reduces platelet activation by 
inhibiting COX-1 leaving the 12-LOX pathway unaffected. Hence, I was interested to 
investigate the potential of DGLA to enhance the anti-platelet effects of aspirin. 
Measuring aggregation of platelets is a key methodology to determine their 
response to different stimuli or anti-platelet treatments. In this thesis, I utilized LTA, 
the gold standard for testing platelet responsiveness 163, and Optimul platelet 
aggregometry that was developed by my lab 6 years ago 164. During Optimul, 96-well 
plates allow the screening of a large array of different concentrations and treatment 
options, whereas LTA can only run a maximum of 8 samples simultaneously 
(depending upon the particular aggregometer). Therefore, I utilized Optimul to 
investigate the concentration-dependent effects of ω-6 PUFAs on platelet function. 
While DGLA, LA and SA did not promote aggregation in unstimulated platelets, LA 
and DGLA caused a concentration-dependent inhibition of aggregation in response 
to different agonists. That DGLA inhibits platelet aggregation has been well studied 
and has been linked to the production of PGE1 and 12-HETrE 106,109,148,161. Although 
Optimul only measures endpoint aggregation, LTA interrogates time-dependent 
processes such as disaggregation and measures aggregation under stirring 
conditions, so I further examined aggregation utilizing LTA in response to DGLA in the 
absence and presence of aspirin 
Inhibition of aggregation in response to LA and DGLA in the LTA was 
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consistent with findings during Optimul and I showed that addition of aspirin 
enhanced disaggregation of platelets, thereby even further decreasing aggregation. 
Both assays have benefits and limitations, however, for my specific study Optimul 
displays a variety of advantages over LTA. During Optimul, agonists are applied via a 
multichannel pipette that minimizes replication errors. Additionally, only 40μl PRP 
per well is needed, in contrast to LTA that requires 180μl per measurement. 
Preparation of the Optimul plates depends on lyophilization, in which the agonists 
are freeze-dried on gelatine-coated plates overnight. This procedure is especially 
beneficial for my project as fatty acids are relatively unstable and quickly oxidize 
during preparation 244. To prevent oxidation, fatty acids are prepared and stored in 
ethanol 233,, however, platelets are highly sensitive to ethanol and become lysed at 
concentrations over 0.05%. Fortunately, the lyophilization step used in the Optimul 
approach allows the ethanol to evaporate while the fatty acids are transferred on to 
the plate. Following preparation, Optimul plates are vacuum-sealed, foil-packed and 
can be stored at room temperature for up to 12 weeks 164. Each preparation run 
allows the production of up to 40 plates, which greatly minimizes the risk of 
variations between experiment sets. Even though Optimul offers a variety of 
advantages, there are also some difficulties involved. The preparation of the plates 
takes a long time and expensive equipment such as a freeze dryer is required. 
Additionally, it must be ensured that the agonist is directly applied into the wells 
which can be difficult due to the small amounts needed (4 -5μl). By investigating the 
effects of DGLA on aggregation with multiple independent assays, I was able to 
demonstrate the robustness of my findings and confirm that DGLA truly inhibits 
platelet aggregation. 
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 In my studies I also show that DGLA potentiates the inhibitory effects of P2Y12 
antagonists, and platelets treated with aspirin plus DGLA required notably lower 
concentrations of additional P2Y12 antagonist for fully inhibited aggregation. In the 
clinic, doses of P2Y12 inhibitors necessary to significantly reduce platelet inhibition 
and improve primary endpoints such as myocardial infarction or stroke have been 
linked to higher rates of bleedings 247. Therefore, this may have important implication 
for the use of DGLA in clinical practice with the aim to potentially reduce the doses 
of P2Y12 antagonist and/or aspirin required for anti-thrombotic therapy and so 
reduce accompanying side effects. Clearly, studying efficacy and toxicity of DGLA in 
whole blood and in vivo is essential before moving on to clinical studies, although, 
oral administration of 10g/kg DGLA did not show any toxicological changes in a rat 
model 248 and supplementation with DGLA (450mg, 4 weeks 249 or 0.5g twice a day 
for two weeks, then 1g every morning for one week followed by 1g twice a day for 
one week 109) safely increases serum and phospholipid DGLA content in healthy 
volunteers with no significant changes in blood pressure, bleeding or other 
haemostatic parameters. Encouragingly, sustained supplementation with at least 1g 
DGLA daily for 4 weeks led to reduction in ex vivo platelet aggregation 109. 
Another indicator of platelet function is the expression of platelet activation 
markers and the ability of platelets to adhere and spread on surfaces. In these 
experiments, I found that DGLA inhibited PS exposure and activation of the integrin 
αIIbβ3 receptor, essential for aggregation and adhesion. In line with this finding, I 
showed that, in addition to aggregation, DGLA also decreases adhesion and 
spreading of platelets to fibrinogen coated coverslips and did so to a greater degree 
than aspirin. Besides decreased αIIbβ3 activation which indicates impaired inside-out 
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signalling, decreased stabilization of platelet adhesion, aggregate formation and 
inhibited granule secretion suggests inhibition of outside-in signalling 250. 
In addition to functional assays, various studies have used proteomic 
techniques to examine the effect of anti-platelet drugs on platelet function 251,252 and 
to identify biomarkers 253,254 or novel targets for therapeutic treatments relevant to 
cardiovascular disease 255. Release of proteins via granule and EV secretion is an 
important part of normal platelet function and studying the underlying processes 
might offer insights into the potential changes in secretion mechanisms that follow 
from exposure to fatty acids. My proteomic studies were founded upon a 3-month 
secondment at the Conway Institute at the University College Dublin. My previous 
functional studies, investigating the aggregatory response of WPs to increasing 
concentrations of ω-6 PUFAs, had already allowed me to identify that the 
concentrations necessary in experiments with PRP to affect aggregation (up to 
1000μM) produced unspecific effects in WPs. As a result, I used lower concentrations 
(10 - 50μM) of the fatty acids for assays in WPs. 
Similar to observations from other groups 56, treatment of aspirin caused a 
strong clustering of proteins for each individual. This appears to suggest that each 
individual responds to aspirin in a way that significantly distinguishes their proteome 
release response from each other. The process and individual consequences behind 
this are unclear. However, it has been widely recognized that the response to anti-
platelet drugs, including aspirin and P2Y12 antagonists, can vary between patients, 
with some experiencing drug resistance, recurrent thrombotic events or even side 
effects such as gastrointestinal bleeding. These different responses have been linked 
to several factors including genetic variations and drug-drug interactions 34,56,256,257, 
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but it is difficult to marry these observations with results from conventional platelet 
aggregometry 258. Perhaps using proteomics to characterise platelets from patients 
with differential responses to anti-platelet drugs could help to refine anti-platelet 
therapies towards a personalized approach and help us understand why some people 
have particular reactions to specific drugs while others do not. Indeed, two separate 
studies have already shown differences in the platelet proteome between aspirin-
resistant and sensitive cardiovascular disease patients with alterations in important 
proteins such as those linked to cell survival and oxidative stress 259,260. This leads me 
to the idea that such individuals could benefit from addition of DGLA to further alter 
eicosanoid production and reduce platelet reactivity independent of aspirin. 
While the other fatty acids did not show a significant effect on the proteomic 
release profile of platelets, DGLA caused a significant concentration-specific shift in 
the released proteins and this effect was even stronger when platelets were exposed 
to DGLA following aspirin treatment. Analysis of the proteomic profile and 
investigations of granule markers via flow cytometry showed that DGLA inhibits 
granule secretion. Additionally, I investigated EVs present in platelet releasate, but 
my measurements did not provide robust data sufficient to investigate the effects of 
DGLA and/or ASA.  
IPA analysis of the proteomic data predicted that addition of DGLA to aspirin-
treated platelets would further inhibit platelet aggregation and adhesion, as I had 
noted in my previous functional studies and is consistent with the hypothesis that 
DGLA increases aspirin-mediated inhibition by influencing secretion and the 
secondary wave of aggregation. Further IPA predictions that DGLA treatment of 
platelets would decrease inflammation and increase vascular repair are very exciting 
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and offer interesting areas for future research. That DGLA can produce beneficial 
effects beyond simply affecting platelet adhesion and aggregation has already been 
indicated in a study showing that DGLA reduces both chemotaxis of monocytes and 
foam cell formation 261.  
Building upon my in vitro data it would be very interesting to conduct a series 
of in vivo studies focussing upon the interaction of DGLA with aspirin. My laboratory 
group has recently developed a platelet selective COX-1 knockout mouse that models 
the human effects of low dose aspirin 262. This would make a very interesting model 
to test the effects of DGLA, for instance, in a model of in vivo thrombosis in the first 
instance. Before moving into in vivo conditions, it would also be beneficial to repeat 
experiments in whole blood from both these mice and wild type mice to investigate 
the interaction of other blood cells, such as leukocytes, with platelets in the presence 
of DGLA. It needs to be kept in mind, that transcellular eicosanoid production can 
influence the outcome, as DGLA can also be metabolized by other cell types that 
express 12-LOX and COX-1 263. 
Cytoskeletal rearrangement is a key process underlying aggregation, 
adhesion and protein secretion, so I was interested to investigate the effects of DGLA 
on the formation of actin and tubulin complexes. Research studying direct 
association of fatty acids to the cytoskeleton is rather limited. It has been shown that 
lipids labelled with palmitic acid can link to the cytoskeleton upon platelet activation 
but that this is not seen with LA or AA. The authors suggested that this incorporation 
may play a role in early-stage aggregation and specifically at the sites of platelet-
platelet interaction. In the same study, granule release was found to be unrelated to 
lipid incorporation 264. In my studies I found that aspirin had no effect on the 
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cytoskeleton whereas DGLA prevented reorganisation following activation. 
Additionally, I observed DGLA to promote an elongated platelet phenotype that has 
not been previously reported. Due to the general paucity of other data in this area, I 
can only speculate as to what mechanisms underlie the above mentioned effects.  
One hypothesis could be that DGLA, as a PUFA with double bonds, is 
incorporated into the membrane and consequently changes membrane fluidity and 
so influences the cytoskeletal structure and receptor expression. Studies 
investigating the expression of specific markers, such as stomatin, flotillin, or CD36, 
for localization of lipid rafts 265 would be useful to further investigate changes in 
membrane fluidity. Unfortunately, the small size of platelets does not allow the use 
of immunofluorescent-based approaches to study distinct areas of the membrane 
which limits the possible experimental approaches. Additionally, it has been 
indicated that it requires PUFAs with 4 or more double blonds such as AA, EPA or 
DHA, to increase membrane fluidity 266, again suggesting that DGLA-specific 
mechanisms might be involved.  
Alternatively, PUFAs can cause cell death when supplied in elevated, unbound 
form, which includes necrosis 267, apoptosis 130 and other forms of regulated cell 
death 268, which may explain the reduction in platelet reactivity that we observe. A 
variety of events have been linked to platelet death including increased EV blebbing 
and PS externalization 269. As DGLA did not consistently enhance EV release and on 
the contrary, inhibited PS exposure, it seems clear that in my experimental conditions 
DGLA does not promote platelet death. More work is needed to fully confirm those 
findings. 
I also found that DGLA increases the release of motor and cytoskeletal 
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proteins which might explain the failure of platelets to reorganize their tubulin and 
actin filaments. In the experiment investigating cytoskeletal arrangement with DGLA, 
inhibition of microtubule alteration was especially notable, as activated platelets still 
displayed a clear marginal band in the presence of DGLA. The marginal band consists 
of dynamic tubulin polymers that polymerize upon platelet activation and cause 
cytoskeletal rearrangement. Several motor proteins, such as dynein, attach to 
microtubules and promote transport of cargo via vesicle release 270 and microtubule 
extensions 59 by sliding along the filaments in a complex with the cofactor dynactin. 
In my proteomic study, I found that dynactin is lost to a greater extent in activated 
platelets treated with DGLA. A study has shown that disruption of dynein/dynactin 
interaction in yeast has caused reduced microtubule depolarization and the 
appearance of an extra-long microtubule phenotype 271, which is similar to my 
findings. It also has been speculated that depolarization of the actin cytoskeleton 
may prevent microtubule coiling as it serves as a scaffold for dynein anchoring. 
Another family of cytoskeletal proteins that are released more when platelets are 
exposed to DGLA are the septins (SEPT 6, 7 and 25). Septins are GTPases that form 
complexes and interact with the plasma membrane as well as with the marginal 
microtubule band. As linker proteins, septins control the connection between the 
plasma membrane and the cytoskeleton, keeping both in proximity. The complex of 
SEPT 5-6-7 has been especially associated with the microtubule network by 
mediating granule transport and secretion 12 and destabilization of this complex has 
been linked to disruption of the microtubule system 11. Talin, another cytoskeletal 
protein that is released more following DGLA treatment, binds to the αIIbβ3 receptor 
and its depletion leads to decreased platelet aggregation and adhesion 13. As well as 
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tyrosine kinase CSK 15 , tropomyosin 16 and myosin-9 59 that are essential for 
stabilization and contraction of actin-myosin fibres, DGLA caused an increased 
release of chaperons, specifically HSPs. These include HSP90AB1, mitochondrial 
HSPE1 as well as HSPA5, HSPA8 and HSP7C, members of the HSP70 family. Their 
functions are diverse, from being involved in protein folding and trafficking to serving 
as scaffolds for large catalytic complexes 210. While small HSPs are essential for actin 
integrity, both HSP90 and HSP70 play critical roles in platelet responses by 
interaction with the microtubule network 272, ensuring correct protein confirmation 
and function during stress responses. Inhibition of HSP70 has shown to inhibit 
platelet shape changes, adhesion and spreading, as well as decreased platelet 
aggregation and p-selectin expression 14. Together, this suggests that loss in 
important cytoskeletal proteins with DGLA treatment, might be one of the drivers for 
loss in platelet function and inhibited cytoskeletal arrangement. Further experiments 
studying the presence of specific proteins using western blot analysis, ELISA or 
immunofluorescence would be beneficial and may confirm whether DGLA-treated 
platelets lose these proteins following activation. Additionally, research on what 
releasate mechanisms are used to dispose of these proteins, if not increased EV 
secretion, and if the elongated phenotype of those platelets is the reason or the 
result of the lost cytoskeletal proteins would offer interesting insights into the 
complex responses of platelets to DGLA. Unfortunately, these studies are beyond the 
scope of this current project. 
While it cannot be excluded that DGLA causes physicochemical changes in 
platelets, an extensive amount of literature has linked platelet responses to PUFAs 
with their derived eicosanoids and associated platelet signalling pathways. As a 
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result, I investigated the eicosanoid profile following from exposure of platelets to 
AA, LA and DGLA alone or in the presence of aspirin. AA-derived mediators and their 
functions are well studied, however, only a limited amount of literature is available 
on LA- and DGLA derived eicosanoids.  Even though the main focus of this thesis 
investigation lays on DGLA, LA has also shown promising effects by inhibiting 
aggregation and the stimulating production of a variety of anti-aggregatory 
eicosanoids such as 9- and 13-HODE 230,231. The effects of the eicosanoids derived 
from DGLA have been discussed in detail in the relevant chapter (Chapter 6 -  
Investigating the effect of ω-6 PUFAS on eicosanoid production) with PGE1 and 12-
HETrE being the most studied in the literature. Consequently, it would be beneficial 
to repeat some of the experiments, especially immunofluorescence analysis of the 
cytoskeleton, following exposure of platelets to the individual eicosanoids or after 
treatment with the 12-LOX inhibitor ML355 84 to better understand the role of 
separate DGLA-derived mediators in these processes. Measurement of eicosanoids 
following dual treatment of platelets with aspirin plus DGLA appeared to promise a 
way to investigate such processes in more depth, but both experiments, investigating 
general eicosanoids from platelet releasate and targeted DGLA-derived eicosanoids 
from platelet lysate, produced unexpected data that I could not reconcile even after 
extensive review of existing literature. While it would be an exciting possibility that 
those data contain innovative findings, i.e. the production of LXs from a pure platelet 
population independent of the formation of LTA4 or the production of DGLA-derived 
prostaglandins despite aspirin treatment, I have to acknowledge the possibility of 
performance errors in LC-MS/MS. LC-MS/MS is a very complex approach and the 
uncertainty of my results highlights the importance of cautious protocol execution 
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and careful discussion of the acquired data with additional experiments to confirm 
various findings.  
While it is difficult to discuss the potential effects and mechanisms of novel 
DGLA-derived eicosanoids due to the lack of literature, it has been indicated that 
PGE1 and 12-HETrE, inhibit platelet activation and aggregation via the cAMP/PKA 
pathway (figure 7.1). As discussed in two independent publications 106,107, both 
mediators bind to the IP receptor that is linked to adenylate cyclase via a Gs-protein, 
resulting in elevation of intraplatelet cAMP. cAMP activates PKA, which then 
phosphorylates a variety of proteins, such as vasodilator-stimulated phosphoprotein 
(VASP) and reduces platelet activation. These considerations offer interesting 
insights into intracellular signalling pathways that might be mediated by DGLA. A 
recent finding showed that the platelet proteome of coronary ischemic patients with 
type 2 diabetes who had received clopidogrel plus aspirin demonstrated a reduction 
in proteins linked to cytoskeletal arrangement compared to patients receiving aspirin 
alone 273. As clopidogrel, a P2Y12 inhibitor, and DGLA-derived eicosanoids both act via 
the cAMP/PKA pathway, this could indicate an involvement of this signalling cascade 
in loss of cytoskeletal integrity. I would have liked to conduct experiments utilizing 
specific inhibitors influencing this pathway, such as H89, a PKA inhibitor, or SQ22536, 
inhibitor for adenylate cyclase, that would have helped to shed light on the 
mechanisms behind those responses.  
Activation of cAMP/PKA can lead to the phosphorylation of a variety of 
proteins important for platelet function. One of those proteins is the myosin light 
chain (MLC), a small peptide subunit of myosin. A study has indicated that PGE1 
inhibits platelet shape changes by preventing phosphorylation of MLC, that, in turn, 
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inhibits binding of myosin to actin and reduces contractile ability 274. MLC can be 
phosphorylated via two different pathways. Firstly, by inhibition of Ca2+-independent 
MLC phosphatase (MLCP) and secondly by activation of the Ca2+/calmodulin-
dependent MLC kinase (MLCK). In the study mentioned above, the authors showed 
that activated cAMP/PKA signalling in response to PGE1 results in sustained MLCP 
activity and subsequent MLC dephosphorylation 274. In previous experiments, I have 
shown that platelets release larger amounts of MLCK and cAMP-dependent protein 
kinase catalytic subunit beta (PRKACB) when treated with DGLA. Release of PRKACB 
strengthens the hypothesis of increased PKA activity following from exposure to 
DGLA, as an increase in cAMP results in release of catalytic subunits from activated 
PKA 275. Loss of MLCK might offer an alternative explanation to why MLC may not be 
phosphorylated. Alternatively, it has been found that PKA-mediated phosphorylation 
inhibits the inositol trisphosphate receptor, and thereby Ca²⁺ mobilisation 276, which 
is essential for MLCK activation 277. As my IPA analysis indicated a potential decrease 
in intracellular Ca²⁺ following exposure to DGLA, directly measuring intracellular Ca²⁺ 
in treated platelets would be a logical further investigation. Additionally, 
investigating the phosphorylation state of target proteins via western blot, ELISA or 
flow cytometry may help to shed light on the involvement of the cAMP/PKA pathway 
following DGLA treatment. 
To summarize, inhibition of cytoskeletal rearrangement which is crucial for 
functional aggregation, adhesion, granule secretion and receptor expression, is, in 
my opinion, the most likely explanation for the diminished platelet reactivity seen 
with DGLA. This process may be inhibited by loss of essential cytoskeletal proteins 
mediated by mechanisms that are still unclear, and/or the likely phosphorylation of 
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target proteins important for cytoskeletal integrity, such as MLC 274 by activation of 
the cAMP/PKA pathway following from activation of particular receptor systems e.g. 
Gs-coupled IP receptor by DGLA-derived eicosanoids. CAMP/PKA activation also 
stimulates phosphorylation of proteins that are directly linked to reduced platelet 
function, e.g. it inhibits integrin αIIbβ3 receptor activity via inside-out signalling, and 
has the potential to decrease intracellular Ca2+ 276. Impaired aggregate stability, 
granule secretion and adhesion capacity with DGLA also suggests an inhibitory effect 
on αIIbβ3 outside-in signalling 250. Inhibition of granule secretion and with that 
reductions in the release of pro-aggregatory proteins such as vWF will further 
attenuate platelet activation and may also influence inflammation and other 
responses in the vascular system. Additional exposure of these platelets to aspirin 
further decreases platelet activity via inhibition of TXA2-dependent pathways. 
This thesis offers new insights into the responses of platelets to DGLA and 
suggests that DGLA may have potential as an adjunct therapy to aspirin and P2Y12 
receptor antagonists by targeting platelet responses (summary of findings in figure 
7.2) for protection against atherothrombotic events. 
 
 
 
 
 
 
 
 
173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fi
gu
re
 7
.1
 S
u
gg
es
te
d
 p
la
te
le
t 
ac
ti
va
ti
o
n
 s
ig
n
al
lin
g 
p
at
h
w
ay
s 
in
fl
u
e
n
ce
d
 b
y 
D
G
LA
 
A
s 
p
re
se
n
te
d
 in
 t
h
is
 t
h
es
is
, d
ih
o
m
o
-γ
-l
in
o
le
n
ic
 a
ci
d
 (
D
G
LA
) 
al
te
rs
 a
 v
ar
ie
ty
 o
f 
p
la
te
le
t 
fu
n
ct
io
n
s 
(i
n
d
ic
at
e
d
 in
 r
ed
).
 T
h
es
e 
re
sp
o
n
se
s 
m
ig
h
t 
b
e 
m
ed
ia
te
d
 
b
y 
b
in
d
in
g 
o
f 
D
G
LA
-d
er
iv
ed
 m
ed
ia
to
rs
 p
ro
st
ag
la
n
d
in
 E
1
 (
P
G
E 1
),
 1
2
(S
)-
h
yd
ro
xy
ei
co
sa
te
tr
ie
n
o
ic
 a
ci
d
 (
1
2
-H
ET
rE
) 
an
d
 p
o
te
n
ti
al
ly
 o
th
er
 e
ic
o
sa
n
o
id
s 
to
 t
h
e 
IP
 r
ec
e
p
to
r 
le
ad
in
g 
to
 t
h
e 
ac
ti
va
ti
o
n
 o
f 
a 
va
ri
et
y 
o
f 
si
gn
al
lin
g 
p
at
h
w
ay
s 
(s
u
gg
es
te
d
 p
at
h
w
ay
s 
th
at
 m
ig
h
t 
b
e 
in
vo
lv
ed
 a
re
 in
d
ic
at
e
d
 in
 g
re
en
. 
Fo
r 
m
o
re
 
d
et
ai
l 
re
fe
r 
to
 t
e
xt
).
 A
D
P
, 
ad
en
o
si
n
e 
d
ip
h
o
sp
h
at
e
; 
TR
A
P
-6
, 
th
ro
m
b
in
 r
ec
ep
to
r 
ac
ti
va
to
r 
p
ep
ti
d
e 
6
; 
vW
F,
 v
an
 W
ill
eb
ra
n
d
 F
ac
to
r;
 P
2
Y 1
/P
2
Y 1
2,
 P
2
Y 
p
u
ri
n
o
ce
p
to
rs
 1
/1
2
; P
A
R
1
, p
ro
te
as
e
-a
ct
iv
at
ed
 r
ec
e
p
to
rs
 1
; 
G
P
V
I, 
gl
yc
o
p
ro
te
in
 V
I;
 G
P
, g
ly
co
p
ro
te
in
; T
X
A
2R
, t
h
ro
m
b
o
xa
n
e 
A
2 
re
ce
p
to
r;
 E
R
, e
n
d
o
p
la
sm
ic
 
re
ti
cu
lu
m
; 
A
TP
, 
ad
en
o
si
n
e 
tr
ip
h
o
sp
h
at
e;
 c
A
M
P
, 
cy
cl
ic
 a
d
en
o
si
n
e 
m
o
n
o
p
h
o
sp
h
at
e
; 
C
a2
+ ,
 c
al
ci
u
m
; 
cP
LA
2
, 
ca
lc
iu
m
-d
ep
en
d
en
t 
p
h
o
sp
h
o
lip
as
e 
A
2;
 I
P
3
, 
In
o
si
to
l t
ri
sp
h
o
sp
h
at
e;
 P
LC
, p
h
o
sp
h
o
lip
as
e 
C
; 
P
IP
2
, p
h
o
sp
h
at
id
yl
in
o
si
to
l 4
,5
-b
is
p
h
o
sp
h
at
e;
 D
A
G
, d
ia
cy
lg
ly
ce
ro
l;
 P
K
C
, p
ro
te
in
 k
in
as
e 
C
; 
A
A
, a
ra
ch
id
o
n
ic
 
ac
id
; 
C
O
X
-1
, c
yc
lo
o
xy
ge
n
as
e
-1
; T
X
A
2
, t
h
ro
m
b
o
xa
n
e 
A
2
. 
174 
 
 
Figure 7.2 Summary of effects of DGLA and anti-platelet therapies on platelet function as 
demonstrated in this thesis 
 
Dihomo-γ-linolenic acid; DGLA 
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APPENDICES 
 
 
Appendix 1 Enriched Reactome pathways from 580 proteins released from platelets. 
Platelets were treated with aspirin and/or AA, LA, DGLA and stimulated with 1U/ml 
thrombin. Protein interaction of released proteins with enriched pathways was analysed 
with STRING. 
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Appendix 2 Effect of DGLA or aspirin alone or as dual treatment on aggregation of platelets 
stimulated with 1U/ml thrombin. Aggregation was measured via LTA. Results are shown as 
mean ± SEM, n=4. One-way ANOVA and Dunnett's multiple comparisons test were used to 
test for statistical difference vs. vehicle 
 
 
Appendix 3 Production of TXB2 and PGE2 from platelets exposed to DGLA alone or in 
combination with aspirin 
Thromboxane B2 (TXB2) and prostaglandin E2 (PGE2) were measured in lysate from platelets 
pre-treated with aspirin (ASA; 30μM) or vehicle and exposed to dihomo-γ-linolenic acid 
(DGLA; 1000μM) for 3min. Platelets were stimulated with thrombin (1U/ml) and eicosanoids 
detected using liquid chromatography tandem mass spectrometry analysis. One-way ANOVA 
and Tukey's multiple comparisons test were used to test for statistical difference vs. vehicle. 
